



**HAL**  
open science

## Probing heterotrimeric G protein activation: applications to biased ligands.

Colette Denis, Aude Saulière, Ségolène Galandrin, Jean-Michel Sénard, Céline Galés

### ► To cite this version:

Colette Denis, Aude Saulière, Ségolène Galandrin, Jean-Michel Sénard, Céline Galés. Probing heterotrimeric G protein activation: applications to biased ligands.. *Current Pharmaceutical Design*, 2012, 18 (2), pp.128-44. inserm-00662107

**HAL Id: inserm-00662107**

**<https://inserm.hal.science/inserm-00662107v1>**

Submitted on 23 Jan 2012

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# Probing heterotrimeric G protein activation: applications to biased ligands

Colette Denis <sup>1\*#</sup>, Aude Saulière <sup>1\*#</sup>, Ségolène Galandrin <sup>2</sup>, Jean-Michel Sénard <sup>1</sup>, Céline Galés <sup>1\*</sup>

<sup>1</sup> I2MC, Institut des maladies métaboliques et cardiovasculaires INSERM : U1048 , Hôpital de Rangueil, 1 av du Prof Jean Poulhes BP84225 31432 Toulouse Cedex 4,FR

<sup>2</sup> IPBS, Institut de pharmacologie et de biologie structurale CNRS : UMR5089 , Université Paul Sabatier - Toulouse III , 205 Route de Narbonne 31077 TOULOUSE CEDEX 4,FR

\* Correspondence should be addressed to: Colette Denis <colette.denis@inserm.fr >, Aude Saulière <Saulière >, Céline Galés <Celine.Gales@inserm.fr >

# These authors contributed equally to this work.

## Abstract

Cell surface G protein-coupled receptors (GPCRs) drive numerous signaling pathways involved in the regulation of a broad range of physiologic processes. Today, they represent the largest target for modern drugs development with potential application in all clinical fields. Recently, the concept of “ligand-directed trafficking” has led to a conceptual revolution in pharmacological theory, thus opening new avenues for drug discovery. Accordingly, GPCRs do not function as simple on-off switch but rather as filters capable of selecting activation of specific signals and thus generating textured responses to ligands, a phenomenon often referred to as ligand-biased signaling. Also, one challenging task today remains optimization of pharmacological assays with increased sensitivity so to better appreciate the inherent texture of ligand responses. However, considering that a single receptor has pleiotropic signalling properties and that each signal can crosstalk at different levels, biased activity remains thus difficult to evaluate. One strategy to overcome these limitations would be examining the initial steps following receptor activation. Even if some G protein-independent functions have been recently described, heterotrimeric G protein activation remains a general hallmark for all GPCRs families and the first cellular event subsequent to agonist binding to the receptor. Herein, we review the different methodologies classically used or recently developed to monitor G protein activation and discuss them in the context of G protein biased -ligands.

**MESH Keywords** Animals ; Drug Discovery ; methods ; Heterotrimeric GTP-Binding Proteins ; metabolism ; Humans ; Ligands ; Receptor Cross-Talk ; Receptors, G-Protein-Coupled ; agonists ; metabolism ; Signal Transduction

**Author Keywords** GPCRs ; G protein ; biased agonist ; ligand-directed trafficking ; ligand efficacy ; G protein sensors ; signaling pathways

## INTRODUCTION

G protein-coupled receptors (GPCRs) represent the largest family of transmembrane receptors and are virtually involved in the regulation of all physiological processes. They represent therefore a primary target for modern drugs development with potential application in all clinical fields. It has been estimated that some 30–50% of clinically available drugs target the function of GPCR family members [1–3]. These receptors propagate highly diverse extracellular signals into the cell interior by interacting with a broad range of intracellular proteins [4]. However, coupling with  $\alpha\beta\gamma$ -trimeric G proteins remains the common hallmark of all GPCR family members and these proteins constitute one of the earliest plasma membrane transducers, relaying information from the cell surface receptor to others intracellular signaling molecules. Recently, GPCRs were found not to work linearly as simple on/off switches, triggering the full signaling machinery downstream the receptor, but rather as filters capable of activating a subset of specific effectors and fine tuning cellular responses and associated physiological responses. This concept, known as “ligand-directed trafficking” or “biased-agonism”, emphasizes that receptors are capable of generating textured responses to ligands [5]. On the other hand, the efficacy of ligands acting on GPCRs may be different depending upon the cellular effector considered [6, 7]. In keeping with these different concepts, it follows that the choice of cellular effectors to measure receptor activation is crucial and that different signaling pathways should be considered in order to appreciate the real texture of ligand effects. However, pleiotropic and crosstalk signaling between GPCRs makes functional selectivity of ligands difficult to decode. One alternative to bypass this problem might be to look at the initial step following agonist binding to receptors at the level of the plasma membrane: i.e. G protein activation. This review will focus on the heterotrimeric G proteins with a specific emphasis on the different tools available to evaluate receptor-mediated G protein activation.

## HETEROTRIMERIC G PROTEINS STRUCTURE

The discovery of heterotrimeric G proteins relaying information from receptors inserted in plasma membrane to intracellular effectors revolutionized our view of how ligands functions. Alfred G. Gilman and Martin Rodbell were jointly awarded the Nobel Prize in Physiology or Medicine in 1994, “for their discovery of G-proteins and the role of these proteins in signal transduction in cells” [8, 9].

G proteins are heterotrimeric proteins consisting of  $G\alpha$ ,  $G\beta$  and  $G\gamma$  subunits tightly associated and bound to the inner face of the cell plasma membrane (Fig.(1)), where they predominantly relay receptor activation. To date, 16 different  $G\alpha$  subunit encoding genes, 5  $G\beta$  subunit genes and 12  $G\gamma$  subunit genes have been described in humans [10]. Additional variants can be generated by alternative splicing

and post-translational processing, leading to up to 23 different G $\alpha$  subunits isoforms. Even if theoretically more than one thousand of distinct heterotrimers may exist, it has been shown that all combinations may not be relevant in signal transduction [11]. Moreover, the nature of the heterotrimer depends on the cell type [12].

The G $\alpha$  subunit (Fig. (1)) is composed of an intrinsic GTPase domain involved in GTP binding and hydrolysis but also in interactions with G $\beta\gamma$  subunits, receptor and effectors [13]. This domain is characterized by three flexible loops identified as switches I, II and III and regulates G protein activation through very subtle conformational rearrangements. The  $\alpha$  subunit exhibits an additional helical domain connected to the GTPase domain by the flexible linker 1 acting as a lid over the nucleotide binding pocket [14, 15]. All G $\alpha$  subunits (except G $\alpha_i$ ) are palmitoylated and/or myristoylated at their N-terminus allowing anchor age to the plasma membrane.

The G $\beta$  subunit (Fig. (1)) shows a peculiar beta-propeller structure with seven WD-40 repeats. The N-termini of G $\gamma$  and G $\beta$  subunits make extensive contacts through a coiled coil interaction all along the base of G $\beta$ . Therefore, G $\beta$  and G $\gamma$  subunits are tightly associated and may be separated only under denaturing conditions. Examination of crystal structures of different heterotrimers revealed two sites of interaction between G $\alpha$  and G $\beta\gamma$ , involving switches I and II and the amino-terminal helix of G $\alpha$  [16, 17]. G $\gamma$  subunits exhibit farnesylation or geranylgeranylation modifications cooperating in trans with G $\alpha$  acylation to allow proper targeting of G $\alpha\beta\gamma$  trimers from the endoplasmic reticulum to the plasma membrane [18]. As G $\beta$  subunits lack lipid modifications, G $\gamma$  subunits act as chaperones for G $\beta$  targeting to the plasma membrane.

Several receptor regions contact surfaces of all three subunits [13, 19] (Fig. (1)). Both N- and C-terminal regions of G $\alpha$  subunits have been implicated in receptor interaction. However, the C-terminus plays a crucial interaction point since derived peptides can directly compete for the coupling of the G protein with the receptor (See section 6.1). G $\beta\gamma$  subunits enhance receptor-G $\alpha$  interaction but can also directly interact with the receptor through their C-terminal regions. The receptor regions involved in these interactions localized to the intracellular loops and the C-terminal tail. Basic amino acids sequences in both the N-terminal and C-terminal part of the third intracellular loop appear particularly important. The C-terminal tail of the receptor also determines important interactions with G $\beta$  subunit. It is of note that today, we still do not understand the molecular basis for the selectivity of G protein coupling to the receptor.

## THE HETEROTRIMERIC G PROTEIN ACTIVATION CYCLE

According to classical dogma, the heterotrimeric G protein activation cycle operates as follows (Fig. (2)). In the absence of receptor stimulation, G $\alpha$  and G $\beta\gamma$  remain associated in a GDP-bound, inactive form physically dissociated from the receptor. Agonist binding to the receptor initiates conformational changes allowing coupling with G $\alpha\beta\gamma$ . This interaction initiates G protein activation which then enters the "GTPase cycle" [8, 17, 20]. The activated receptor acts as a guanine nucleotide exchange factor (GEF), promoting a conformational change in G $\alpha$  and ensuing GDP release. GTP, in much higher concentrations than GDP in the cytosol, then binds to G $\alpha$ , switching its conformation to the active state. In the traditional view of heterotrimeric G protein activation, GDP/GTP exchange drives the dissociation of G $\alpha$  from G $\beta\gamma$  and the receptor ("collision model"). However, recently, several groups have suggested a new model where nucleotide exchange only promotes structural rearrangements within preformed receptor-G protein complexes ("conformational model") [21, 22]. The dissociated G $\alpha$ -GTP and G $\beta\gamma$  can activate different effectors and signaling cascades (ion channels, enzymes...). Termination of the signal is facilitated by the inherent GTPase catalytic activity of G $\alpha$  which hydrolyses GTP to GDP, and allows reassociation of G $\alpha$  with G $\beta\gamma$ . Then, the G protein initiates a new cycle. To date, although we distinguish different G $\alpha$  subunits isoforms functionally, they all share a similar mechanism of activation.

GDP/GTP exchange and GTP hydrolysis represent two limiting steps in the G protein activation cycle. They are tightly regulated by accessory proteins which accelerate or impede these events by modulating kinetic constants and differ according to the G $\alpha$  isoform. These numerous regulatory proteins were reviewed by Sato *et al.* [23] and may act as:

- GEFs (guanine nucleotide exchange factors), such as AGS1, Ric-8, GAP-43 for example. These regulators interact with G $\alpha$ , likely in a subtype-specific manner, and stimulate the exchange of GDP for GTP to accelerate the generation of the active form.
- GDIs (guanosine nucleotide dissociation inhibitors), such as AGS3, AGS4, AGS5, RGS12, RGS14. In contrast to GEFs, GDIs stabilize G $\alpha$  in an inactive GDP-bound conformation. Most of these proteins possess a 19–30 amino acids conserved motif named GPR (G protein regulatory) or GoLoco ("G $\alpha_{i/o}$ -Loco" interaction) motif which specifically interacts with G $\alpha_{i/o}$  subunits and is directly involved in prevention of GDP dissociation but also in G $\alpha$ -G $\beta\gamma$  reassociation. In fact, these proteins exhibit dual functions: they may hinder signaling through G $\alpha_{i/o}$  by stabilizing the GDP-bound conformation, but they may also sustain G $\beta\gamma$ -dependent activation by inhibition of G $\beta\gamma$  association with GDP-G $\alpha$  [24].
- GAPs (GTPase-activating proteins) which antagonize GEFs activity and accelerate GTP hydrolysis back to GDP, thus favoring the G protein resting state and termination of G protein signaling. They act allosterically to stabilize the transition state occurring during GTP hydrolysis and promote reassociation of G $\alpha$  and G $\beta\gamma$ . Some G protein-regulated effectors can also exhibit GAP activity such as

phospholipase C- $\beta$  activated by  $G_q$  and p115RhoGEF activated by  $G_{\alpha_{13}}$ . Among GAPs, RGSs (regulators of G protein signaling) represent the largest family with more than 20 members identified so far [25].

## DIFFERENT CLASSES OF HETEROTRIMERIC G PROTEINS FOR ACTIVATION OF DIFFERENT EFFECTORS

G proteins are classified into four families, based on the homology of the primary sequence of the  $G\alpha$  subunit and to some extent, the selectivity of effectors activation (reviewed in [26, 27]) (Fig.(3)).

The  $G_{\alpha_s}$  family is composed of four isoforms, produced by alternative splicing, with a ubiquitous distribution, and  $G_{\alpha_{olf}}$  which has a more restricted expression in olfactory neurons. These G proteins directly stimulate transmembrane adenylyl cyclases (AC) leading to the production of cAMP. These proteins were also shown to stimulate GTPase activity of tubulin and Src tyrosine kinase. They are substrate for ADP-ribosylation mediated by cholera toxin responsible for inhibition of GTPase activity and the permanent activation of  $G_{\alpha_s}$ .

The  $G_{\alpha_{i/o}}$  family comprises the ubiquitous  $G_{\alpha_{i1}}$ ,  $G_{\alpha_{i2}}$ ,  $G_{\alpha_{i3}}$  but also  $G_{\alpha_{oA}}$  and  $G_{\alpha_{oB}}$  which are predominantly expressed by neurons and neuroendocrine cells. Also included in this group and with restricted distribution, are  $G_{\alpha_z}$  which can be found in platelets and neurons,  $G_{\alpha_{t1}}$  and  $G_{\alpha_{t2}}$  expressed in retina and  $G_{\alpha_{gust}}$  in taste buds. They all inhibit adenylyl cyclase activity and decrease intracellular cAMP levels. Beyond AC, most of the isoforms can also activate  $K^+$  channels or inhibit  $Ca^{2+}$  channels. All these subunits can be ADP-ribosylated and inactivated by pertussis toxin.

The  $G_{\alpha_{q/11}}$  family, including  $G_{\alpha_q}$ ,  $G_{\alpha_{11}}$ ,  $G_{\alpha_{14}}$ ,  $G_{\alpha_{15}}$  and  $G_{\alpha_{16}}$  isoforms, stimulates membrane-bound phospholipase C- $\beta$ , which hydrolyses phosphatidyl 4,5-diphosphate (PIP2) into two second messengers, inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). IP3 is responsible for  $Ca^{2+}$  liberation from intracellular stores, while DAG activates protein kinase C. Other effectors are also cited in the literature as, for example, p63-RhoGEF and  $K^+$  channels.

The  $G_{\alpha_{12/13}}$  family comprises only 2 members to date ( $G_{\alpha_{12}}$  and  $G_{\alpha_{13}}$ ) with a ubiquitous expression profile. They regulate Rho family GTPase signaling through RhoGEF activation and control cell cytoskeletal remodeling, thus regulating key biological processes such as cell migration. They can also activate a large panel of different effectors such as radixin, A-kinase anchoring proteins, phospholipases D, protein phosphatase 5.

$G\beta\gamma$  complexes, initially thought to only favor  $G\alpha$  anchorage to the plasma membrane and to stabilize the inactive state of  $G\alpha$ , are now known to mediate many functional responses on their own following GPCRs activation (reviewed in [12]). Many effectors can be activated by interaction with  $G\beta\gamma$  subunits such as  $K^+$  channels (GIRK 1,2,4), phospholipases C- $\beta$ , adenylyl cyclase (II,IV,VII), Src kinases, while others will be inhibited such as, adenylyl cyclase I,  $Ca^{2+}$  channels (N, P/Q, R types). The  $G\beta\gamma$  dimer composition seems to be essential in dictating the specificity of both receptors and the effectors for their coupling to the G protein [10]. Although  $G\beta\gamma$  is always depicted as an inseparable dimer, several works have suggested the existence of  $G\beta$  or  $G\gamma$  monomer activity (reviewed in [10]) and recently it was demonstrated that  $G\beta$  can activate *K. lactis* pheromone pathway in the absence of the  $G\gamma$  subunit [28].

## INDIRECT ASSAYS TO ASSESS RECEPTOR-MEDIATED G PROTEIN ACTIVATION

GPCRs ligands are usually classified according to their receptor specificity and intrinsic activity. Originally, this classification was essentially based on the effect of ligands on the activity of only the primary effector pathway, usually involving second messenger generation, which is generally assigned to the receptor of interest. According to their relative efficacy compared with the physiological agonist, ligands were identified as partial or full agonists when able to induce a fraction or a full response respectively, whereas neutral antagonists were believed to be devoid of effect and inverse agonists allow the inhibition of constitutive activity.

### $G_s$ - $G_i$ activation

Both  $G_s$  and  $G_i$  proteins predominantly act by activating or inhibiting adenylyl cyclase respectively and thus regulating intracellular ATP conversion into cAMP (Fig. (3)). The direct measurement of adenylyl cyclase activity is possible using [ $\alpha$ - $^{32}$ P] ATP as the enzyme substrate [29]. However, most investigators usually determine intracellular cAMP levels. The intracellular cAMP concentration is regulated by the balance between production rate by adenylyl cyclases and degradation rate by phosphodiesterases. Historically, cAMP was the first second messenger quantified in living cells and its measure has been widely used to test ligands acting on  $G_s$ - and  $G_i$ -coupled receptors. The early development of cAMP antibodies [30] allowed the development of Radioimmunoassays (RIA), Enzyme Immunoassays (EIA), Chemiluminescent Immunoassays (CLIA) and more recently Homogeneous Time Resolved Fluorescence (HTRF) assay, motivated by the desire to move away from the use of radioactivity. These methods are now very sensitive (detection of less than one femtomole) and adapted to a homogenous format allowing their use in the context of ligand screening in pharmaceutical industry. However, they cannot follow kinetics of cAMP levels fluctuations in living cells as they consist essentially of static measurements after

cell lysis and based on the accumulation of cAMP in the presence of a phosphodiesterase blocker so to increase cAMP levels and enhance detection sensitivity. Another disadvantage of current cAMP assays to assess ligand efficacy may be the global cAMP levels evaluation of the cell since cAMP signal was shown to be compartmentalized within the cell and local responses may thus be diluted in the general background [31]. During the last few years, fluorescent-based sensors evaluating spatiotemporal resolution of cAMP signals in living cells have been extensively developed [32]. All of these approaches rely on the use of genetically encoded fluorescent reporters using cAMP binding properties of cAMP downstream effectors, protein kinase A (PKA) and Epac (exchange proteins directly activated by cAMP). After cell transfection of the biosensor, accurate monitoring and visualizing of the cAMP dynamics in the different cell compartments is possible by measuring FRET (fluorescence resonance energy transfer). Sensing of cAMP can rely on conformational changes of the biosensor when the reporter is solely based on the use of the cAMP binding domain of the effector as for the Epac-based biosensor [33] or on the behavior of the entire effector as for protein kinase A sensor measuring dissociation of its regulatory and catalytic subunits which occurs after cAMP binding [34]. Similar strategies were applied using BRET-based biosensors [35] based on the use of luminescence probes which offer better sensitivity and wide dynamic range of detection. Such probes are suitable tools for screening of new ligands for GPCRs. However, despite their high sensitivity, all these techniques remain indirect readouts of the G protein activation since their focus on the evaluation of cAMP downstream signaling. More recently, Pantel *et al.* described a more direct cAMP detection system using a genetically modified luciferase whose activity is restricted to the cAMP binding domain of RII $\beta$  subunit of the PKA (pGloSensor™, Promega) [36]. When coexpressed with the melanocortin-4 receptor, this cAMP-luciferase probe demonstrated very high sensitivity allowing detection of inverse agonist activity of ligands in the absence of PDE inhibitor. Despite promise, this latter method requires use of stably transfected cells for high efficiency as it was poorly reproducible in transiently transfected cells (unpublished data from our lab). Another recent technology for direct cAMP detection using luminescence as a read-out and based on enzyme fragment complementation technology (Discoverex, CA) offers great utility and sensitivity for a large panel of both G<sub>s</sub>- and G<sub>i</sub>-coupled GPCRs with large range dynamics for inhibitory signals (unpublished data from our lab).

Another specific difficulty to evaluate ligand efficacy at the level of cAMP signal emanates from G<sub>i</sub>-coupled receptors. In this case, adenylyl cyclase must be obligatorily pre-stimulated, generally using forskolin, to increase cAMP concentration in order to detect the inhibition of the enzyme in a second step. Despite wide use, this strategy is at risk of biased interpretations since forskolin and G $\alpha_s$  bind different adenylyl cyclase regions and therefore induce different conformations of the enzyme catalytic core [37]. In fibroblast cells overexpressing PTX-insensitive G $\alpha_{i/o}$  proteins, Ghahremani *et al.* have shown that the dopamine G<sub>i</sub>-coupled D2S receptor may inhibit the activity of AC through distinct G $\alpha_i$  proteins [38]. In fact, when adenylyl cyclase is stimulated with forskolin, D2S-induced inhibition of the enzyme is mediated by G $\alpha_{i2}$ , while following activation by PGE1, the receptor inhibits AC through G $\alpha_{i3}$ . This suggests that G $\alpha_{i2}$  and G $\alpha_{i3}$  demonstrate specificity for different conformational states of adenylyl cyclase. Furthermore, differences may also arise from activation specificities among adenylyl cyclase isoforms. It was shown that forskolin preferentially activates AC<sub>I</sub> over AC<sub>II</sub>, AC<sub>V</sub>, or AC<sub>VI</sub>, while G $\alpha_s$  stimulates AC<sub>II</sub> more efficiently than AC<sub>I</sub>, AC<sub>V</sub>, or AC<sub>VI</sub> [39]. Today, evaluating ligand efficacy at G<sub>i</sub>-coupled receptors still remains a challenging task and especially for the detection of weak efficacies, as available cAMP assays provide generally too low dynamic ranges of inhibition detection. To resolve this specific problem to G $\alpha_{i/o}$ -mediated cAMP signals, chimeric G proteins were developed. Basically, this strategy relies on the conversion of the G $\alpha_{i/o}$  into another signaling unit which still relies on the G $\alpha_{i/o}$  activation mode. Generally, conversion is based on the production of another second messenger easy to measure such as Ca<sup>2+</sup> or inositol phosphates. In this context, the first chimeric G protein was designed by substituting three amino acids of G $\alpha_q$  by the corresponding residues of G $\alpha_{i2}$  [40]. This G $\alpha_{q-i2}$  was functionally expressed and induced PLC activation (G $\alpha_q$  effector) through the stimulation of G<sub>i</sub>-coupled receptors, demonstrating that the chimera keeps G<sub>i</sub> specificity [40]. Due to its ability to associate with multiple receptors without high selectivity [41], G $\alpha_{i16}$  was then thought to be the optimal G protein backbone for the generation of G protein chimera to obtain a truly universal G protein adaptor stimulated by all the GPCRs. However, several G<sub>i</sub>-linked receptors and also some G<sub>s</sub>-linked receptors are unable to activate PLC via G $\alpha_{i16}$ . To optimize the G $\alpha_{i16}$  so to enlarge its binding capacity to a maximum of receptors, different chimeras were constructed by incorporating variable length of G $\alpha_z$  (G $\alpha_{i/o}$  family) or G $\alpha_s$  sequences into the C terminus of G $\alpha_{i16}$  and were highly efficient to mediate both G<sub>i</sub> and G<sub>s</sub> dependent-G<sub>i16</sub> signaling [42, 43]. Finally, further analysis revealed that the G $\alpha_{i16-z}$  chimera is able to transmit signal from virtually all G protein-linked receptors (G<sub>i</sub>-, G<sub>s</sub>- and the G<sub>q</sub>) [44]. Another chimera has been generated based on the mutation of a critical amino acid located in the linker region connecting the GTPase and the helical domain of the G $\alpha_q$  protein. Hence, the mutant acquires the capacity to transmit G<sub>i</sub>- and G<sub>s</sub>- linked GPCR signals [45]. Further additional mutations in the C-terminus of G $\alpha_q$  combined with the linker mutation led to an optimized "universal" G protein chimera now functional for all the three G protein families [46]. Even if these artificial chimeras are far from the reality of natural G proteins, they remain very attractive tools to screen for ligands at GPCRs especially for orphan GPCRs [47, 48], at least at first instance.

## G<sub>q</sub> activation

To test ligands efficacy on G<sub>q/11</sub>-coupled receptors, different assays have been developed to measure inositol phosphate or calcium concentrations as reflects of PLC activity (Fig. (3)). Original methodologies for determination of PLC activity used artificial phospholipid vesicles containing [<sup>3</sup>H]-inositol PIP<sub>2</sub> and enzyme activity was measured by following the amount of [<sup>3</sup>H]-inositol triphosphate (IP<sub>3</sub>)

released into the aqueous solution [49]. This technique was improved by Mullinax *et al.* who developed labeled phospholipids bound on microplates [50]. However, this technique is only suitable for cell extracts or permeabilized cells. More classically used for the investigation of G<sub>q/11</sub>-coupled receptors is the monitoring of inositol phosphate derivative production. The radiolabelled precursor, [<sup>3</sup>H] *myo*-inositol, is incorporated into intact cells as [<sup>3</sup>H]-phosphatidylinositol 4,5-bisphosphate. Upon agonist binding to the receptor, PI<sub>4,5</sub>P<sub>2</sub> are hydrolyzed by PLC into [<sup>3</sup>H]-IP<sub>3</sub> and DAG. LiCl must be added to prevent dephosphorylation of IP<sub>3</sub> and to increase sensitivity. The mass of soluble IP<sub>3</sub> is a quantitative readout of receptor activation. [<sup>3</sup>H]-IP<sub>3</sub> is quantified following purification on anion-exchange chromatography or by HPLC [51, 52]. HPLC also allows quantification of the production of the other inositol phosphates [53]. As for cAMP, specific IP<sub>3</sub> antibodies allowed development of several specific and sensitive immunoassays. Other assays using IP<sub>3</sub> binding proteins competition can also be used and were proposed for high-throughput screening of GPCR ligands [54]. However, IP<sub>3</sub> production is very transient due to its extremely short half life making it difficult to accurately quantify. By comparison, IP<sub>1</sub>, a downstream metabolite of IP<sub>3</sub>, is stable in the presence of LiCl providing a better read out of G<sub>q</sub>-coupled receptors. Thus, IP<sub>1</sub>-based immunoassays have been developed and offer both high sensitivity and assay window. This sensitive technique already allowed the detection of inverse agonist activity at mGlu5 receptor [55] and is readily adaptable to high-throughput screening assays to screen for ligands efficacy.

A common alternative to explore ligand efficacy at G<sub>q</sub>-coupled-receptor is the evaluation of calcium mobilization. In response to PLC activation, IP<sub>3</sub> produced in the cytoplasm, binds to endoplasmic reticulum IP<sub>3</sub> receptors thus liberating calcium from internal stores. Specific dyes generating fluorescence upon binding of free Ca<sup>2+</sup> have been developed since almost 30 years. Most of them derive from calcium chelators EGTA or BAPTA fused with an additional acetoxymethylester (AM) group to allow cell penetration. Once in the cell, AM is cleaved by endogenous esterases and the intracellular probe then becomes active. A number of chemical calcium indicators are now available and the investigator must consider the Ca<sup>2+</sup> affinity of the probe which must be compatible with the intracellular concentration of Ca<sup>2+</sup> to measure. Spectral properties of the indicators can also differ, varying from single wavelength to ratiometric indicators. The different criteria to select the suitable probe were recently reviewed with advantages and limitations discussed for each probe [56]. These indicators are very powerful tools, easy to use and to calibrate, and suitable for cell imaging. However, they present some limitations to their use. First, they act *per se* as Ca<sup>2+</sup> buffers and can therefore influence Ca<sup>2+</sup> levels and kinetics and, second, their cellular localization cannot be controlled or targeted. The other alternative is the use of genetically encoded luminescent proteins. Aequorin was the first Ca<sup>2+</sup>-sensitive photoprotein isolated from the jellyfish *Aequorea Victoria* [57]. In the presence of Ca<sup>2+</sup>, the photoprotein undergoes a conformational change allowing oxidation of its substrate coelenterazine into coelenteramide. Upon relaxation, this product goes from an excited state to the ground state and emits a flash blue light (469 nm). The great advantage of aequorin is that it can be targeted to several intracellular cell compartments (nucleus, endoplasmic reticulum (ER), Golgi apparatus, mitochondrial matrix, mitochondrial intermembrane space, plasma membrane) by direct fusion of specific targeting sequences, thus offering the possibility of subcellular Ca<sup>2+</sup> measurements. Generally, G<sub>q</sub>-coupled receptors mediated Ca<sup>2+</sup> signals are often monitored using mitochondrial-aequorin, because ER has close physical relationship with mitochondria and the release of Ca<sup>2+</sup> from ER exposes mitochondria to very high Ca<sup>2+</sup> concentrations [58]. However, when compared with fluorescent dyes, this approach, which necessitates a transfection step, is not easy to calibrate and not sensitive enough for cell imaging since one molecule of aequorin will produce only a single photon. To overcome some of these limitations, others Ca<sup>2+</sup>-sensitive fluorescent proteins have been developed, such as the cameleon conformational FRET sensors. These biosensors were initially based on tandem repeats of mutants fluorescent proteins (Blue or Cyan mutant GFP and Green or Yellow mutant GFP) used as FRET donors and acceptors, interconnected by a Ca<sup>2+</sup>-sensitive linker of calmodulin fused to peptide M13 (a calmodulin binding peptide from myosin light-chain kinase). Upon Ca<sup>2+</sup> binding, calmodulin forms a compact complex with the M13 domain and this intramolecular rearrangement modifies FRET between the fluorescent proteins [59]. These probes have been further improved and present now expanded dynamic range. Others FRET-based Ca<sup>2+</sup> indicators, such as pericams and camgaros, have also been developed (reviewed in [60]) and are amenable for high throughput screening in drug discovery [61].

### G<sub>12/13</sub> activation

The evaluation of G<sub>12/13</sub> activation still remains problematic, essentially because we still have not identified their specific direct effectors as compared with the other G protein families. Since they were found to regulate actin cytoskeleton remodeling, G<sub>12/13</sub> proteins have been essentially studied in the context of cell proliferation, migration and morphology where they have been shown to regulate many diverse effectors (Fig. (3)). Thus, given their biological action, they elicit the interest of a large number of research groups especially for the chemokine receptors for which they play major role in regulating chemotaxis process. However, quantitative measurement of G<sub>12</sub>/G<sub>13</sub> activation remains a challenging task today. Usually, evaluation of G<sub>12/13</sub> activation is based on measurement of downstream effectors. The common effector downstream of G<sub>12/13</sub> activation appears to be the Rho guanine nucleotide exchange factors (RhoGEFs), which can be visualized by immunoblotting techniques, with limited sensitivity for accurate evaluation of ligand efficacy [62, 63]. However, measuring RhoGEFs activation does not ensure G<sub>12</sub>/G<sub>13</sub> activation readout since most of the G<sub>12/13</sub>-coupled receptors also couple to other G protein

isoforms such as  $G_{q/11}$  which can also converge on RhoGEF activation. Specific identification of  $G_{12}/G_{13}$ -dependent receptor signaling can be evaluated by siRNA knockdown strategy but it only remains qualitative. Thus, to date,  $G_{12/13}$  activation is not appropriate for evaluation of ligand efficacy.

All together, these strategies involving measurement of effector activity and/or second messenger production have been greatly improved during the last few years and are valuable for the study of the effects of GPCR ligands. However, they suffer from some general limitations. First, they are distal events following interaction of the ligand with the GPCR and may be subjected to amplification and compartmentalization which cannot always be readily appreciated. Second, most receptors generally simultaneously activate different G protein isoforms. Therefore, assessment of receptor activity at the level of second messenger increases the occurrence of cross-talks thus making evaluation of ligand efficacy complicated. That is, signaling becomes more complicated to analyze when one looks farther from the initiating event of receptor activation at the plasma membrane. One strategy to overcome these limitations would be examining the initial step of receptor activation common to all GPCR families which is the direct activation of heterotrimeric G proteins. Indeed, G proteins represent the only signaling relay common to all GPCRs and their activation is the first step consequent to receptor stimulation. For these reasons, an accurate method to depict the intrinsic activity of ligands would be to determine unequivocally their activation profile on different G protein isoforms. Several methods have been developed to evaluate G protein activation which are more or less adapted to accurate ligand efficacy assessment.

## DIRECT ASSAYS TO ASSESS RECEPTOR-MEDIATED G PROTEIN ACTIVATION

### General pharmacological tools

When available, pharmacological inhibitors targeting specific G protein families provide powerful tools to study the involvement of these proteins in GPCR signal transduction by preventing associated downstream signaling.

Pertussis toxin (PTX), formerly called Islet Activating Protein (IAP), isolated from *Bordetella pertussis*, catalyses ADP-ribosylation of all  $G_{i/o}$  subunits which subsequently remain locked in their inactive state, thus unable to activate its effectors. This mechanism prevents  $G_{i/o}$  proteins from functionally interacting with GPCRs. PTX have been largely used to characterize involvement of  $G_{i/o}$  proteins in receptor signaling in many cellular models. Recently, the role of  $G_{i/o}$  protein was studied *in vivo* using transgenic mice expressing the PTX catalytic subunit specifically in pancreatic islet [64]. Mastoparan, a peptide toxin from wasp venom, can also interfere primarily with  $G_{i/o}$  proteins [65]. It promotes dissociation of GDP and accelerates GTP binding on  $G_{i/o}$  subunits thus mimicking an agonist-bound receptor. A mastoparan derivative, mastoparan-S, was described to selectively activate  $G_{s}$  [66]. Cholera toxin from *Vibrio cholerae*, targets specifically intracellular  $G_s$  proteins and induces their constitutive activation by permanent ADP-ribosylation [67]. The toxin was quite useful in the purification and characterization of  $G_s$  proteins [68]. The search for specific  $G_s$  inhibitors led to the identification of suramin, an anti-helminthic drug, and its derivatives that directly interact with G proteins and interfere with GTP binding on both  $G_s$  and  $G_{i/o}$  proteins [69]. Some suramin analogues, NF449 and NF503, appear to be specific for  $G_{\alpha_s}$  and to block the coupling of  $\beta$ -adrenergic receptors to  $G_s$  in S49 cyc - cells [70].

The  $G_q$ -dependent signaling pathway can also be modulated by recently discovered molecules: *Pasteurella multocida* toxin (PMT) and YM-254890. PMT is a bacterial toxin activating  $G_{q/11}$  proteins, but the molecular mechanism underlying G protein activation is unknown [71]. However, PMT was also suggested to activate others signaling pathways such as  $G_{12/13}$  and Rho proteins [72, 73]. YM-254890, a cyclic depsipeptide isolated from culture of *Chromobacterium* sp. QS3666, appears as a potent and specific inhibitor of the  $G_{q/11}$  family [74]. It prevents the GDP/GTP exchange reaction on  $G_{\alpha_q}$ ,  $G_{\alpha_{11}}$  and  $G_{\alpha_{14}}$  isoforms by inhibiting the GDP release. Recent analysis of the X-ray crystal structure of the  $G_{\alpha_q}\beta\gamma$ -YM-254890 complex showed that YM-254890 binds specifically to the linker domain connecting the helical from the GTPase domain of  $G_{\alpha_q}$ , thus preventing flexibility during the  $G_{\alpha}$  activation process [75]. More recently, Ayoub *et al.* have described another small molecule BIM-46187, as a non-specific and ubiquitous inhibitor of receptor-G protein signaling through selective binding to the  $G_{\alpha}$  subunit [76]. This pan-inhibitor of GPCR signaling might be useful to dissect G protein -dependent and -independent signaling pathways.

An alternative approach for the identification of selective G protein-dependent pathways is the use of synthetic peptides mimicking the COOH-terminus of the different  $G_{\alpha}$  subunits which compete with  $G_{\alpha}$  subunit binding to the receptor and thus inhibit G protein dependant signaling. In fact, the COOH-terminal part of  $G_{\alpha}$  subunits is critical for both the interaction with their cognate receptors and the specificity of each  $G_{\alpha}$  isoform. These G protein inhibitors were first used in permeabilized cells where they were able to block the stimulation of adenylyl cyclase mediated by  $\beta$ -adrenergic receptors [77]. The technique was further extended with the generation of minigene plasmid vectors encoding the C-terminal peptide sequence of most  $G_{\alpha}$  subunits facilitating their expression in living cells by transfection or infection [78]. However, since the peptides act as competitive inhibitors and thus must be expressed in the cell at high concentrations for high efficiency, one has to be cautious on the results interpretations as they will largely depend on the transfection/expression efficacy of

the peptides [79]. Obviously, this will also vary between cell lines as they usually have different G protein complements [80]. By opposition to chemical G protein inhibitors, which only allows discrimination between G protein families, this strategy further permits the dissection of G protein isoforms involved in receptor-mediated signaling.

Participation of specific G proteins in *in vivo* signal transduction has been extensively elucidated using G protein-deficient mouse models allowing classical or conditional inactivation of the genes encoding the different G protein subunits. Several knockout mice models lacking expression of one or two G $\alpha$  subunits or G $\beta\gamma$  subunits have been generated and the consequences of the genetic disruption on physiology and pathophysiology have been extensively reviewed [81]. Another similar strategy is the knockdown of G $\alpha$  and G $\beta$  subunits through small interfering RNA, adapted to *in vitro* studies [82]. Although these genetic strategies provide high specificity of inactivation between the different and closely related G protein subunits, they can be subject to compensatory mechanisms by modifications of the expression levels of other endogenous G proteins, thus interfering with the results interpretation.

Although all these methods are quite useful, they still remain qualitative in that they just help in the dissection of molecular mechanisms underlying G protein-dependent receptor signaling. However, they cannot replace direct measurement of the protein activity as a quantitative assessment of G protein activation.

### **[<sup>35</sup>S]GTP $\gamma$ S binding**

The most common technique to directly measure G proteins activation following agonist stimulation is the [<sup>35</sup>S]GTP $\gamma$ S binding assay monitoring the nucleotide exchange process in membranes extracts, which was first described by Hilf *et al.* [83]. This radioactive GTP analog binds the G $\alpha$  subunit following activation but resists GTPase hydrolysis, thus stabilizing the G $\alpha$  in the active form and preventing G protein activation cycle arrest. Therefore, G $\alpha$ -[<sup>35</sup>S]GTP $\gamma$ S subunits accumulate and radioactivity can be counted following filtration procedures to separate bound from free radioactivity. As [<sup>35</sup>S]GTP $\gamma$ S cannot cross plasma membranes, the assay is restricted to cell membrane preparations or permeabilized cells [84]. The method was also used in tissue sections and autoradiography allowing anatomical localization of activated G proteins [85]. The pharmacology of a large panel of GPCRs ligands has been largely investigated by the use of this method (reviewed in [86]), thus allowing accurate characterization of their G protein potency and efficacy. The [<sup>35</sup>S]GTP $\gamma$ S binding method provides a sensitive tool to characterize constitutive activity of receptors through identification of inverse agonists [87] but also to evaluate antagonist activity by the shift of agonist-induced dose-response curves (pA<sub>2</sub> value determination). While it proves to be a powerful assay to evaluate G<sub>v/o</sub>-coupled receptor activation, a major pitfall of this method comes from its low sensitivity to analyze receptors coupled to others G protein families, essentially due to a poor signal to background ratio. Indeed, PTX-sensitive G proteins generate optimal results most probably because of their generally higher expression levels in most mammalian cells and their greater nucleotide exchange rate. Even though suitable for the measurement of endogenous G protein activity, a large number of [<sup>35</sup>S]GTP $\gamma$ S experiments were performed in heterologous expression systems stably or transiently expressing receptor and/or different G protein subtypes of interest; however, competition with endogenously expressed G proteins may confuse the issue. Thus, cell lines expressing low levels of mammalian G protein such as Sf9 insect cells have also been used [88, 89]. In all cases, changing both the receptor and G protein stoichiometry may profoundly influence ligand pharmacology, for example, the relative potency of agonists as discussed by Kenakin in the light of the concept of ligand-selective receptor conformations [90]. This has led to the conception of receptor-G $\alpha$  fusion proteins, forcing a 1:1 expression ratio, which will be discussed below. Beside potency modulation, G protein subtype overexpression may modify ligand efficacy at G proteins as well and thus reveal protean agonism of ligands as shown for  $\alpha_{2A}$ -adrenergic receptor [91].

Even if [<sup>35</sup>S]GTP $\gamma$ S binding accurately measures direct G protein activity, it cannot provide information about the subtypes specificity of the activated G protein and therefore has been further improved. Thus, the existence of selective antisera for the different G $\alpha$  subunits allows immunocapture and thus enrichment of G proteins of interest following [<sup>35</sup>S]GTP $\gamma$ S binding [92, 93]. Immunoprecipitation of the G protein can also be coupled to scintillation proximity assays (SPA) to eliminate unbound radioactivity separation steps and may be applied to high-throughput screening [94, 95]. In this method, G protein immunoprecipitation is followed by a second immunoprecipitation of the radioactive G protein immuno-complex using specific beads containing scintillant and coated with a non specific anti-IgG. When [<sup>35</sup>S] is in close proximity to the scintillant, it generates a luminescent signal detected by a microplate scintillation counter. However, the problem of antibody specificity and immune-capture efficiency remains an impediment to these assays. Other modifications of the initial [<sup>35</sup>S]GTP $\gamma$ S assay use non-radioactive GTP analogs. Among them, Europium-labeled GTP appears to be an interesting alternative in HTRF-based detection assays [96, 97]. Fluorescent BODIPY® GTP $\gamma$ S analogs may also be used [98] but need further validation because of their non negligible hydrolysis rate by G $\alpha_{v/o}$  subunits [99].

The receptor-G protein (R-G) fusion strategy was developed during the 90's to force a 1:1 stoichiometry efficient coupling of a given receptor to a specific G protein subunit [100] and has subsequently been applied to a large number of receptors [101–103]. This technique relies on the fusion of the G $\alpha$ -protein subunit N-terminus to the receptor C-terminus in a single open reading frame, leading to the expression of a unique polypeptide containing both functionalities. G protein activation is then assessed according to [<sup>35</sup>S]GTP $\gamma$ S binding performed on cell membranes expressing the R-G fusion construct, allowing evaluation of the role of the G protein isoform on the potency/efficacy of different ligands. Using this technique, different  $\beta_2$ -adrenergic agonists showed different pharmacological profiles



(potency and efficacy) depending on the  $G\alpha$ -protein subunits fused to the  $\beta_2$ -receptor [104]. This approach also proved useful in the context of protean agonism revealing for instance that one dopamine receptor ligand could behave as an agonist or an antagonist depending on the D2R- $G\alpha$ -subunit pair considered [103]. Beyond G protein activity, the use of R-G fusions was an ingenious and well-adapted strategy to study G protein transactivation mechanisms mediated by GPCR dimers [105–107]. Also true for classical [ $^{35}$ S]GTP $\gamma$ S binding assays using endogenous G proteins, the main drawback of the R-G fusion activation measurement is probably competition by endogenous receptors and/or G proteins which can result in a poor signal to noise ratio. To bypass this problem,  $G\alpha_{i/o}$  PTX-resistant isoforms can be used, coupled with PTX pre-treatment of cells to neutralize endogenous  $G\alpha_{i/o}$  isoforms [102]. However, this issue still persists for all other G protein families ( $G_s$ ,  $G_{q/11}$ ,  $G_{12/13}$ ). Another concern is the non-dynamic measurement of R-G activity since the  $G\alpha$  subunit is irreversibly fused to the receptor and thus could give rise to artefactual interpretations. Finally, an additional problem comes from the fusion of the G protein to the C-terminus of the receptor by itself that can impair the proper trafficking of the receptor to the plasma membrane and/or its pharmacological properties (ligand binding/activation process). Also, an accurate characterization of the R-G fusion must precede its subsequent use.

### **Plasmon Waveguide Resonance**

Plasmon waveguide resonance (PWR) spectroscopy is an optical approach derived from Surface Plasmon Resonance and developed by Salamon's group to allow the study of membrane-associated proteins. There is abundant literature dealing with the physical principle of this technique [108, 109]. Briefly, a polarized continuous wave laser is used to excite the resonator which consists in a thin silver film coated by a thicker silica layer deposited onto the surface of a glass prism. Laser excitation generates an evanescent electromagnetic field localized at the outer surface of the silica. Resonance excitation generated depends on the angle of incidence of the laser beam and is modulated by molecules present at the outer surface. The protein of interest is inserted in a single lipid bilayer at the interface between the silica film of the resonator and an aqueous buffer compartment in which molecules can be added [109]. PWR allows real-time measurement of molecule or protein binding to a specific receptor inserted in the lipid bilayer with high sensitivity in the absence of radioactive or fluorescent label. This technique has been used to characterize kinetics and thermodynamics of conformational events associated with the binding of ligands and of G proteins on the  $\delta$ -opioid receptor (DOR) and provided new insights into the function of these molecules [110]. These studies demonstrated that receptor-G protein interactions are quite selective depending both on the ligand-bound states of the receptor but also on the G protein isoforms [110]. Interestingly, by coupling PWR studies of receptor-G protein interaction with GTP $\gamma$ S binding assay examining the G protein activation state, a disconnection between the two events was demonstrated which highlights the existence of a non-active precoupled state of the receptor. Thus, PWR has been demonstrated as a powerful approach to measure selectivity and activity of GPCR ligands towards the different G protein isoforms. This was possible by the use and insertion of different purified G protein isoforms in reconstituted membrane systems containing the receptor and thus allows an acute control of the expression of each protein partners [111]. On the other hand, this method is limited because it is based on artificial cell system reconstitution which does not reproduce the real cellular environment, especially regulations by other cellular proteins which could participate and modify ligand-receptor-G protein relationships. Moreover, PWR requires receptor and G proteins purification steps, thus dramatically impairing its use for large-scale screens. Finally, this approach is hardly accessible to non-specialist researchers, as illustrated by the limited number of GPCR studied to date [110, 112–114].

### **“RETvolution”: monitoring real-time G protein activation in living cells**

The field of cell biology has been subjected to a real shake-up with the introduction of non invasive biophysical RET-based approaches, allowing for the first time, quantification of intracellular signaling events dynamics in real-time and in living cells. The evaluation of receptor-mediated G protein activation did not escape from view using these technologies.

#### ***The RET principle***

The Resonance Energy Transfer (RET) biophysical principle was discovered and published by Theodor Förster in 1940s [115], but its ultimate impact is still evolving. Basically, RET relies on non-radiative energy transfer between an energy donor and an acceptor molecule occurring under highly restrictive distance parameters (Fig. (4A)). When donor and acceptor are in close proximity (distance < 100 Å), the energy generated by donor excitation is then transferred to the acceptor through a non radiative process of resonance, which in turned becomes excited and emits at a different wavelength from that of the donor. Given its distance dependence, RET is highly suitable to monitor protein-protein interactions in living cells between two partners tagged with different RET partners following transfection. Interestingly, the efficiency of RET is inversely proportional to the sixth power of the distance between donor and acceptor dipoles, thus allowing accurate measurement of relatively small variations in distance or orientation between the two RET partners. Thus, RET is suitable not only to measure intermolecular events (protein-protein interactions) but also allows monitoring of intramolecular events like protein conformational changes. Another parameter limiting RET efficiency and fluctuating between energy donor/acceptor couples is the spectral overlap between the emission wavelength of the donor and the excitation wavelength of the acceptor, since acceptor excitation is only dependent on the donor emission. Depending on the nature of the energy donor, RET will be defined as: i/FRET (Fluorescent Resonance Energy Transfer) when using a fluorescent donor and excited by an external energy source (laser or arc lamp), or ii/BRET

(Bioluminescent Resonance Energy Transfer) when using an enzymatic donor (*Renilla* luciferase) and excited by oxidation of its coelenterazine substrate (Fig. (4B) ). Both FRET and BRET use a fluorescent energy acceptor. Because of its fluorescent nature, FRET allows subcellular localization of RET events. However, on the other end, extrinsic donor excitation by a light source has several limitations due to direct excitation of the fluorophore acceptor or photobleaching of the FRET partners and, in the cell context, cell autofluorescence [116]. In this context, BRET is a better choice because of the enzyme-dependent activation of the donor, thus allowing a better signal to noise ratio[116].

Originally, BRET-based approaches used two BRET generations called BRET<sup>1</sup> and BRET<sup>2</sup> based on the use of different luciferases, coelenterazine substrates and fluorescent acceptors conferring specific and distinct spectral properties of the energy donor/acceptor couple [117, 118] (Fig. (5) ). At that time, most of the studies in biology favoured BRET<sup>1</sup>-based approaches over BRET<sup>2</sup>, essentially because of the low luminescence intensity emission of the BRET<sup>2</sup> luciferase, requiring higher expression level of the proteins fused to the different BRET partners. Nevertheless, BRET<sup>1</sup> provides much lower sensitivity due to the considerable overlap between acceptor and donor emission spectra, compared with BRET<sup>2</sup>, for which separation between the two spectra is optimum (Fig. (5) ). It follows that BRET<sup>1</sup> generates higher background compared with BRET<sup>2</sup> and is not optimal for detection of weak RET signals (which can be true especially in the detection of subtle conformational changes) for which BRET<sup>2</sup> seems more suitable. Exactly same problem also applies to FRET and none of the available donor/acceptor couples offers optimum spectrum resolution. Until recently, BRET<sup>1</sup>-based approaches did not justify their continued use as major improvements of BRET<sup>2</sup> luminescence intensity were introduced with the use of a *Renilla* luciferase mutant (Rluc8), demonstrating equal or even higher luminescence intensity compared with BRET<sup>1</sup> [119]. Rluc8-BRET<sup>2</sup> is so sensitive that it can be even used for microscopic detection of BRET in living cells but also in living animals [120]. The main limiting aspects of the use of BRET or FRET approaches are the necessity to transfect cells for introduction of RET-tagged proteins, and the molecular weight of the protein fused to the proteins of interest (27–36 kDa). Thus, it remains essential to control for the biological properties (cell localization, functionality) of the fusion proteins before subsequent RET experiments.

### ***Sensing G protein activation using RET***

In the traditional view of heterotrimeric protein activation (see section 2), the active receptor initiates sequential events based on multiple protein-protein interactions and/or conformational changes: i/receptor-G $\alpha$ GDP- $\beta\gamma$  protein interaction, ii/G $\alpha$ -GDP/GTP exchange, iii/receptor-G protein dissociation and G $\alpha$ -G $\beta\gamma$  dissociation, iv/G $\alpha$ -GTP hydrolysis, v/ G $\alpha$ -GDP and G $\beta\gamma$  reassociation. Thus, this biological process obviously provided an ideal template for RET-based assays development. During the last ten years, several groups have developed different RET-based probes to monitor real-time dynamics of receptor mediated-G protein activation cycle in living cells.

### ***Indirect measurement of G protein activation: receptor-G protein interactions***

G protein activation can be assessed indirectly by RET by monitoring interactions in real time between receptors and G protein subunits in living cells (Fig. (6A) ). For this purpose, BRET or FRET donors and acceptors are fused on the C-terminus of the receptor and in one of the different subunits of the G $\alpha\beta\gamma$  protein and the RET-fusion proteins are then overexpressed in mammalian cells. BRET or FRET were measured between receptor and G $\beta$  or G $\gamma$  subunits tagged at their N-terminus with the BRET partner and further between the receptor and G $\alpha$  subunit [121–124]. Generating G $\alpha$ -BRET probes was not an easy task given the complex structure of the protein compared to G $\beta$  or G $\gamma$  subunits and the relative high size of the BRET partner (around 26–40 kDa) to insert. Actually, several probes were generated based on the G $\alpha$  crystal structures available (unpublished data), but only a few potential insertion sites did not disrupt trafficking and functional properties of the G $\alpha$  subunit. In fact, all studies used intramolecular G $\alpha$ -BRET probes with the RET partner generally introduced in the helical domain of the protein or the linker region connected the helical from the GTPase domain. Although FRET assays failed to detect basal interactions between receptor and G protein subunits[122], by opposition several BRET-based studies clearly monitored constitutive R-G complexes, thus highlighting the existence of preformed R-G complexes [21, 121, 123, 125, 126]. Lack of FRET sensitivity over BRET (see RET principle) may probably account for these discrepancies. In all studies, agonist stimulation of the receptor promoted a rapid (milliseconds) modification of the RET signal between several GPCRs and either G $_s$  or G $_{i/o}$  proteins. Interestingly, depending on the insertion site of the RET partners within the G protein subunit, agonist-stimulation can induce either an increase or a decrease in RET, thus demonstrating that the RET in fact monitors conformational rearrangements within preformed R-G complexes (or occurring during the receptor-G protein interaction step). This notion is supported by a study where three different BRET probes within the G $\alpha_1$  subunit were used to monitor its interaction with the  $\alpha_{2A}$ -adrenergic receptor [21]. Similar results were obtained when measuring the interaction between G protein subunits and the  $\delta$ -opioid receptor [123]. Receptor-G protein RET-biosensors monitoring conformational rearrangements occurring during the activation process are highly prone to pharmacological characterization of ligands. Two comparable studies performed on  $\beta_2$ -adrenergic and  $\alpha_{2A}$ -adrenergic receptors demonstrated that agonist stimulation promoted a concentration-dependent increase in RET between receptor and G $\gamma_2$  in good agreement with second messenger responses [121, 122]. Partial agonist led to a partial BRET modulation compared to the maximal RET signals obtained in the presence of full agonists, while antagonists completely blocked the agonist response. Moreover, RET monitoring of agonist-induced receptor-G $\gamma$  conformation changes shows high selectivity for the coexpressed G $\alpha$  isoforms, despite all G protein subunits being overexpressed (which could favour unspecific coupling), thus demonstrating the intrinsic coupling selectivity of each receptor [121, 125]. Indeed, agonist-induced BRET

increase between the  $G_s/G_i$  coupled  $\beta_2$ -adrenergic receptor and  $G\gamma_2$  was only detected in presence of  $G\alpha_s$  and  $G\alpha_i$  but not with  $G\alpha_q$  or  $G\alpha_{11}$  [121 ] while a FRET increase between the  $G_i$ -coupled protease-activated receptor and  $G\beta\gamma$  was only detected in the presence of  $G\alpha_i$  but not  $G\alpha_s$  [125 ].  $G\alpha$ -specificity of RET changes detected between receptor and  $G\beta\gamma$  subunits was also confirmed for  $G_i$ -coupled-receptors by specific blockage with pertussis toxin pre-treatment [121 ]. Finally, RET analysis of receptor-mediated G protein activation allowed measurement of the real time kinetics of the activation process, on a milli-second time scale following immediate agonist stimulation [21 , 121 , 122 , 125 ]. Although RET-based assays monitoring R-G interactions may provide accurate information about the G protein activation process, it remains an indirect sensor which monitors conformational rearrangements occurring within preformed R-G complexes. It follows that RET-based R-G monitoring does not necessarily corroborate G protein activation state. For instance, the  $\alpha_2$ -adrenergic antagonist RX821002 increases the BRET signal between  $G\alpha_{11}$  and  $\alpha_{2A}$ -adrenergic receptor but is unable to promote  $G\alpha_{11}$  activation [21 ]. The capability of the R-G BRET assay to probe ligand-induced structural rearrangements in preexisting receptor-G protein complexes and leading to changes in the distance between the receptor carboxyl tail and the G protein subunits has profound impact in the field of biased agonists. Actually, if different ligands promote distinct R-G conformational changes through a unique receptor, this could highly suggest that they engage different signaling outputs. Similar approaches allowed characterization of ligand-biased MAPK signaling through the  $\beta_1$ -adrenergic receptor[124 ].

### **Direct measurement of G protein activation: G protein subunits interactions**

According to the classical model of heterotrimeric protein activation, receptor-mediated  $G\alpha$ -GDP/GTP exchange triggers the dissociation of the  $G\alpha$ -GTP from the  $G\beta\gamma$  dimer and the receptor. Obviously, measuring RET between  $G\alpha$  and  $G\beta\gamma$  subunits was identified as the easiest way to directly measure G protein activation (Fig. (6B) ). The first studies measuring FRET between  $G\alpha$  and  $G\beta\gamma$  subunits were carried out in *Dictyostelium discoideum* and yeast and demonstrated good correlations between agonist-mediated BRET modulation and G protein activation [127 ]. Numerous other studies then used FRET or BRET strategies to follow the heterotrimeric G protein activation cycle by measuring  $G\alpha$  and  $G\beta\gamma$  in mammalian cells [21 , 22 , 122 , 123 , 128 –132 ]. In all cases, agonist-promoted decreases in RET between  $G\alpha$  and  $G\beta\gamma$  have been interpreted as evidence of receptor-promoted dissociation of the G protein complex. Although loss of RET is consistent with dissociation, it can also reflect conformational rearrangements that promote an increase in the distance between the two RET partners. Consistent with this latter hypothesis, and as observed for receptor-G protein subunits interactions, the use of RET probes at different positions within the  $G\alpha\beta\gamma$  complex could lead to either an increase or a decrease in RET signals[21 , 133 ]. It follows that when assessing the G protein activation using RET-based methods, the position of the RET partners in the G protein complex appears to be crucial especially for ligand efficacy evaluation. The insertion of the *R luc* at different positions in the  $G\alpha_{11}$  highlighted that insertion after amino acid 91 within the helical domain ( $G\alpha_{11}$ -91R luc) led to a potent and unique direct sensor of G protein activation when measuring its interaction with the energy acceptor GFP10 tagged- $G\gamma_2$  subunit at its N-terminus (GFP10- $G\gamma_2$ ) [21 ] (Fig. (7A) ). This  $G\alpha_{11}$ -91R luc/GFP10- $G\gamma_2$  BRET<sup>2</sup> probe allowed measurement of the greater separation between the  $G\alpha$  helical domain and the  $G\gamma_2$  N-terminus occurring during GDP/GTP exchange that is translated by the BRET sensor as a decrease in BRET following receptor activation (Fig. (7B) ). Indeed, BRET modulations measured in the presence of various  $\alpha_{2A}$ -adrenergic ligands correlated perfectly with their intrinsic signaling efficacy. Agonists induced a potent BRET decrease, partial agonists induced only a fraction of the signal promoted by full agonist while antagonists had no effect. No other probe position used to detect changes within the  $G\alpha\beta\gamma$  complex provided such a direct correlation between signaling efficacy and BRET changes [21 ]. Thus, the  $G\alpha_{11}$ -91 R luc/GFP10- $G\gamma_2$  BRET<sup>2</sup> probe proved to be a potent sensor to monitor the separation of the  $G\alpha$  helical domain and the  $G\gamma$  N-terminus occurring during G protein activation and thus to evaluate receptor ligands efficacy.

RET monitoring receptor-G protein or G protein subunit interactions represents a quite promising approach in the future to dissect GPCRs ligand efficacies most proximal to the receptor. Even if this strategy has only been described for a few  $G\alpha$  RET probes, it could be easily enlarged to all the other  $G\alpha$  subunits for all G proteins family and could thus help unravel potential ligand-biased activity at specific sets of G protein subunits that remains elusive. Another benefit of RET-based assays over other assays is the acute temporal appreciation of signaling events, allowing detection of ligand selectivity at the level of kinetics. Commonly, ligand selectivity is quite apparent in concentration-response curves; however, differences between agonists can only be detectable by kinetics analysis as already reported for  $\beta$ -arrestin translocation [134 ]. Finally, RET-based assays offer the possibility to visualize spatial organization of the signaling and so to dissect biased activity of ligands in terms of signal compartmentalization.

## **G PROTEIN ACTIVATION AND BIASED AGONISM**

Originally, GPCRs were thought to function necessarily through rapid activation of heterotrimeric G proteins, thus propagating the different intracellular signaling pathways. In the last few years, it seems that GPCRs could activate distinct G protein-dependent and -independent transduction pathways and that GPCR ligands, namely biased-ligands, can selectively favour activation of only a subset of the pathways activated by a given receptor. Although GPCRs can modulate a large variety of distinct signaling pathways, classification of

biased-ligands was restricted to two groups depending on their ability to activate two main transduction pathways [135]: i/ G protein-biased ligands which promote G protein activation without  $\beta$ -arrestin recruitment and ii/  $\beta$ -arrestin-biased ligands which recruit  $\beta$ -arrestin to the receptor and initiate consecutive signaling pathways in the absence of G protein activation.

Interestingly, very few ligands have been yet identified as perfect G protein-biased ligands, namely inducing G protein signal transduction without any  $\beta$ -arrestin recruitment [135–137]. For instance, GMME1 ligand binding to the CCR2 receptor led to calcium mobilization, caspase-3 activation and consecutive cell death, but did not recruit  $\beta$ -arrestin2 [138]. Indeed, most of the ligands classified as G protein-biased are less potent for  $\beta$ -arrestin recruitment than for G protein activation but they do activate the  $\beta$ -arrestin pathway [134, 135, 139]. Interestingly, some ligands are biased in regard to the different G protein families [140, 141]. Thus, atosibans electively activates the  $G_i$  pathway after binding to the  $G_{q/i}$ -coupled oxytocin receptor without any  $G_q$ -mediated signal transduction and very little receptor desensitization, thereby leading to the selective inhibition of cell growth [140]. In opposition to G protein biased activity, the vast majority of biased ligands identified so far exhibits exclusive  $\beta$ -arrestin activity for a number of receptors [135, 142], including the AT1 angiotensin II receptor [143],  $\beta_1$ -[144] and  $\beta_2$ -adrenergic receptors [145], or the CXCR7 decoy receptor [146].

Most of biased ligand screening has focused on evaluation of G protein and  $\beta$ -arrestin pathways separately. Many sensitive assays are available to measure different levels of the  $\beta$ -arrestin pathway activation in living cells [147], including  $\beta$ -arrestin translocation assays evaluating  $\beta$ -arrestin recruitment to the receptor [148–151], or measures of different conformational changes of the  $\beta$ -arrestin protein occurring during its activation process [152, 153], to confocal analysis of the spatial redistribution of the receptor/ $\beta$ -arrestin complex [143, 154–156]. On the contrary, direct and accurate evaluation of G protein activation still remains elusive as discussed above. The monitoring of G protein activity in the context of “biased activity” is generally based on the evaluation of its downstream signaling by measuring G protein effectors activation (phosphorylation or second messengers measurement) or by direct evaluation of the G protein activity using the low sensitive assay [ $^{35}$ S]GTP $\gamma$ S binding, which is the most classical method to directly analyse G protein activation but exhibits a poor signal to noise ratio, even with technical improvements, and is not sensitive enough to monitor activity of all G protein families [48, 157]. Given the general low efficacy of biased ligands, [ $^{35}$ S]GTP $\gamma$ S binding assay cannot be adapted to evaluate G protein biased activity. The difficulty to measure G protein biased-activity comes also from the existence of a large panel of  $G\alpha\beta\gamma$  protein subunits combinations compared to the existence of only two  $\beta$ -arrestin ( $\beta$ -arrestin1 and  $\beta$ -arrestin2) that are almost impossible to evaluate individually. Recent development of RET-based probes monitoring the activation of specific  $G\alpha\beta\gamma$  combinations should certainly help in that direction. This raises the question whether  $\beta$ -arrestin biased ligands are truly unable to activate G proteins or if the assays were simply not sensitive enough to detect low levels of G protein activation. Taking into account that biased ligands are generally less potent than full agonists [123, 158, 159], the low-sensitivity of current assays monitoring G protein activation appears to be a limiting step in the global appreciation of G protein biased-ligands. It is interesting to note that most of the work describing  $\beta$ -arrestin-selective signaling never evaluated potential involvement of the G protein component in this pathway, essentially as they failed to primarily identify G protein activity using classical direct assays (which does not mean there is not). Indeed, this could be easily performed by blunting G protein expression and/or activity using siRNA strategy or toxin/chemical inhibitors as mentioned above.  $\beta$ -arrestin siRNA strategies were often used to evaluate implication of this protein in a signaling pathway.

Thus, evaluation of biased activity is not an easy task given the high diversity of GPCRs signaling and the molecular crosstalk which can occur between the different signaling pathways. Restricting evaluation to the G protein and the  $\beta$ -arrestin components appears exclude the full array of signaling pathways linked to a given receptor and their interconnections. G protein and  $\beta$ -arrestin are good examples as, originally, these two proteins were tightly connected given the canonical role of  $\beta$ -arrestin in dampening G protein signaling during desensitization [160] but they also demonstrate independent signaling as shown by the selective G protein or  $\beta$ -arrestin biased activity of ligands. Another difficulty comes from the insufficient sensitivity of the different assays to evaluate activity of the different signaling components which will depend on the ligand efficacy. This highlights the necessity to accurately monitor the various signal transduction pathways in order not to underestimate ligand efficacy. One possibility is to multiplex different assays to evaluate activation of specific effectors. This is currently being done to evaluate  $\beta$ -arrestin-dependant pathways but is still missing for G protein signaling, for which only one assay is generally performed. However, even with accurate  $\beta$ -arrestin and G protein assays, multiplexing assays which will examine different vantage points in the signalosome, from the initial signaling event of receptor/G protein activation at the plasma membrane to the more downstream signaling events inside the cell, will probably be the best way to fully characterize the efficacy of a given ligand completely.

## References:

1. Hopkins AL, Groom CR. The druggable genome. *Nat Rev Drug Discov*. 2002; 1: 727 - 30
2. Vassilatis DK, Hohmann JG, Zeng H, Li F, Ranchalis JE, Mortrud MT. The G protein-coupled receptor repertoires of human and mouse. *Proc Natl Acad Sci U S A*. 2003; 100: 4903 - 8
3. Jacoby E, Bouhelal R, Gerspacher M, Seuwen K. The 7 TM G-protein-coupled receptor target family. *ChemMedChem*. 2006; 1: 761 - 82
4. Ritter SL, Hall RA. Fine-tuning of GPCR activity by receptor-interacting proteins. *Nat Rev Mol Cell Biol*. 2009; 10: 819 - 30
5. Kenakin T. Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. *Trends Pharmacol Sci*. 1995; 16: 232 - 8
6. Kenakin T. Functional selectivity through protean and biased agonism: who steers the ship?. *Mol Pharmacol*. 2007; 72: 1393 - 401
7. Galandrin S, Oligny-Longpre G, Bouvier M. The evasive nature of drug efficacy: implications for drug discovery. *Trends Pharmacol Sci*. 2007; 28: 423 - 30
8. Gilman AG. G proteins: transducers of receptor-generated signals. *Annu Rev Biochem*. 1987; 56: 615 - 49

- 9 . Rodbell M . The role of hormone receptors and GTP-regulatory proteins in membrane transduction . *Nature* . 1980 ; 284 : 17 - 22
- 10 . McIntire WE . Structural determinants involved in the formation and activation of G protein betagamma dimers . *Neurosignals* . 2009 ; 17 : 82 - 99
- 11 . Hynes TR , Mervine SM , Yost EA , Sabo JL , Berlot CH . Live cell imaging of Gs and the beta2-adrenergic receptor demonstrates that both alphas and beta1gamma7 internalize upon stimulation and exhibit similar trafficking patterns that differ from that of the beta2-adrenergic receptor . *J Biol Chem* . 2004 ; 279 : 44101 - 12
- 12 . Dupre DJ , Robitaille M , Rebois RV , Hebert TE . The role of Gbetagamma subunits in the organization, assembly, and function of GPCR signaling complexes . *Annu Rev Pharmacol Toxicol* . 2009 ; 49 : 31 - 56
- 13 . Oldham WM , Hamm HE . Heterotrimeric G protein activation by G-protein-coupled receptors . *Nat Rev Mol Cell Biol* . 2008 ; 9 : 60 - 71
- 14 . Iiri T , Farfel Z , Bourne HR . G-protein diseases furnish a model for the turn-on switch . *Nature* . 1998 ; 394 : 35 - 8
- 15 . Hamm HE . The many faces of G protein signaling . *J Biol Chem* . 1998 ; 273 : 669 - 72
- 16 . Wall MA , Coleman DE , Lee E , Iniguez-Lluhi JA , Posner BA , Gilman AG . The structure of the G protein heterotrimer Gi alpha 1 beta 1 gamma 2 . *Cell* . 1995 ; 83 : 1047 - 58
- 17 . Lambright DG , Sondek J , Bohm A , Skiba NP , Hamm HE , Sigler PB . The 2.0 Å crystal structure of a heterotrimeric G protein . *Nature* . 1996 ; 379 : 311 - 9
- 18 . Michaelson D , Ahearn I , Bergo M , Young S , Philips M . Membrane trafficking of heterotrimeric G proteins via the endoplasmic reticulum and Golgi . *Mol Biol Cell* . 2002 ; 13 : 3294 - 302
- 19 . Bourne HR . How receptors talk to trimeric G proteins . *Curr Opin Cell Biol* . 1997 ; 9 : 134 - 42
- 20 . Bourne HR , Sanders DA , McCormick F . The GTPase superfamily: conserved structure and molecular mechanism . *Nature* . 1991 ; 349 : 117 - 27
- 21 . Gales C , Van Durm JJ , Schaak S , Pontier S , Percherancier Y , Audet M . Probing the activation-promoted structural rearrangements in preassembled receptor-G protein complexes . *Nat Struct Mol Biol* . 2006 ; 13 : 778 - 86
- 22 . Bunemann M , Frank M , Lohse MJ . Gi protein activation in intact cells involves subunit rearrangement rather than dissociation . *Proc Natl Acad Sci U S A* . 2003 ; 100 : 16077 - 82
- 23 . Sato M , Blumer JB , Simon V , Lanier SM . Accessory proteins for G proteins: partners in signaling . *Annu Rev Pharmacol Toxicol* . 2006 ; 46 : 151 - 87
- 24 . Siderovski DP , Willard FS . The GAPs, GEFs, and GDIs of heterotrimeric G-protein alpha subunits . *Int J Biol Sci* . 2005 ; 1 : 51 - 66
- 25 . Ross EM , Wilkie TM . GTPase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins . *Annu Rev Biochem* . 2000 ; 69 : 795 - 827
- 26 . Cabrera-Vera TM , Vanhauwe J , Thomas TO , Medkova M , Preinerger A , Mazzoni MR . Insights into G protein structure, function, and regulation . *Endocr Rev* . 2003 ; 24 : 765 - 81
- 27 . Milligan G , Kostenis E . Heterotrimeric G-proteins: a short history . *Br J Pharmacol* . 2006 ; 147 : (Suppl 1 ) S46 - 55
- 28 . Navarro-Olmos R , Kawasaki L , Dominguez-Ramirez L , Ongay-Larios L , Perez-Molina R , Coria R . The beta subunit of the heterotrimeric G protein triggers the *Kluyveromyces lactis* pheromone response pathway in the absence of the gamma subunit . *Mol Biol Cell* . 2010 ; 21 : 489 - 98
- 29 . Nakai C , Brooker G . Assay for adenylate cyclase and cyclic nucleotide phosphodiesterases and the preparation of high specific activity 32-P-labeled substrates . *Biochim Biophys Acta* . 1975 ; 391 : 222 - 39
- 30 . Steiner AL , Kipnis DM , Utiger R , Parker C . Radioimmunoassay for the measurement of adenosine 3',5'-cyclic phosphate . *Proc Natl Acad Sci U S A* . 1969 ; 64 : 367 - 73
- 31 . Nikolaev VO , Hoffmann C , Bunemann M , Lohse MJ , Vilardaga JP . Molecular basis of partial agonism at the neurotransmitter alpha2A-adrenergic receptor and Gi-protein heterotrimer . *J Biol Chem* . 2006 ; 281 : 24506 - 11
- 32 . Willoughby D , Cooper DM . Live-cell imaging of cAMP dynamics . *Nat Methods* . 2008 ; 5 : 29 - 36
- 33 . DiPilato LM , Cheng X , Zhang J . Fluorescent indicators of cAMP and Epac activation reveal differential dynamics of cAMP signaling within discrete subcellular compartments . *Proc Natl Acad Sci U S A* . 2004 ; 101 : 16513 - 8
- 34 . Zhang J , Ma Y , Taylor SS , Tsien RY . Genetically encoded reporters of protein kinase A activity reveal impact of substrate tethering . *Proc Natl Acad Sci U S A* . 2001 ; 98 : 14997 - 5002
- 35 . Prinz A , Diskar M , Erlbruch A , Herberg FW . Novel, isotype-specific sensors for protein kinase A subunit interaction based on bioluminescence resonance energy transfer (BRET) . *Cell Signal* . 2006 ; 18 : 1616 - 25
- 36 . Pantel J , Williams SY , Mi D , Sebag J , Corbin JD , Weaver CD . Development of a high throughput screen for allosteric modulators of melanocortin-4 receptor signaling using a real time cAMP assay . *Eur J Pharmacol* . 2011 ; 660 : 139 - 47
- 37 . Tesmer JJ , Sunahara RK , Gilman AG , Sprang SR . Crystal structure of the catalytic domains of adenylyl cyclase in a complex with Galpha . *GTPgammaS Science* . 1997 ; 278 : 1907 - 16
- 38 . Ghahremani MH , Cheng P , Lembo PM , Albert PR . Distinct roles for Galphai2, Galphai3, and Gbeta gamma in modulation of forskolin- or Gs-mediated cAMP accumulation and calcium mobilization by dopamine D2S receptors . *J Biol Chem* . 1999 ; 274 : 9238 - 45
- 39 . Sutkowski EM , Tang WJ , Broome CW , Robbins JD , Seamon KB . Regulation of forskolin interactions with type I, II, V, and VI adenylyl cyclases by Gs alpha . *Biochemistry* . 1994 ; 33 : 12852 - 9
- 40 . Conklin BR , Farfel Z , Lustig KD , Julius D , Bourne HR . Substitution of three amino acids switches receptor specificity of Gq alpha to that of Gi alpha . *Nature* . 1993 ; 363 : 274 - 6
- 41 . Offermanns S , Simon MI . G alpha 15 and G alpha 16 couple a wide variety of receptors to phospholipase C . *J Biol Chem* . 1995 ; 270 : 15175 - 80
- 42 . Mody SM , Ho MK , Joshi SA , Wong YH . Incorporation of Galpha(z)-specific sequence at the carboxyl terminus increases the promiscuity of galpha(16) toward G(i)-coupled receptors . *Mol Pharmacol* . 2000 ; 57 : 13 - 23
- 43 . Hazari A , Lowes V , Chan JH , Wong CS , Ho MK , Wong YH . Replacement of the alpha5 helix of Galpha16 with Galphas-specific sequences enhances promiscuity of Galpha16 toward Gs-coupled receptors . *Cell Signal* . 2004 ; 16 : 51 - 62
- 44 . Liu AM , Ho MK , Wong CS , Chan JH , Pau AH , Wong YH . Galpha(16/z) chimeras efficiently link a wide range of G protein-coupled receptors to calcium mobilization . *J Biomol Screen* . 2003 ; 8 : 39 - 49
- 45 . Heydorn A , Ward RJ , Jorgensen R , Rosenkilde MM , Frimurer TM , Milligan G . Identification of a novel site within G protein alpha subunits important for specificity of receptor-G protein interaction . *Mol Pharmacol* . 2004 ; 66 : 250 - 9
- 46 . Kostenis E , Martini L , Ellis J , Waldhoer M , Heydorn A , Rosenkilde MM . A highly conserved glycine within linker I and the extreme C terminus of G protein alpha subunits interact cooperatively in switching G protein-coupled receptor-to-effector specificity . *J Pharmacol Exp Ther* . 2005 ; 313 : 78 - 87
- 47 . Selvam C , Oueslati N , Lemasson IA , Brabet I , Rigault D , Courtiol T . A virtual screening hit reveals new possibilities for developing group III metabotropic glutamate receptor agonists . *J Med Chem* . 2010 ; 53 : 2797 - 813
- 48 . Kostenis E , Waelbroeck M , Milligan G . Techniques: promiscuous Galpha proteins in basic research and drug discovery . *Trends Pharmacol Sci* . 2005 ; 26 : 595 - 602
- 49 . De Vivo M . Assays for G-protein regulation of phospholipase C activity . *Methods Enzymol* . 1994 ; 238 : 131 - 40
- 50 . Mullinax TR , Henrich G , Kasila P , Ahern DG , Wenske EA , Hou C . Monitoring Inositol-Specific Phospholipase C Activity Using a Phospholipid FlashPlate(R) . *J Biomol Screen* . 1999 ; 4 : 151 - 5
- 51 . Dangelmaier CA , Daniel JL , Smith JB . Determination of basal and stimulated levels of inositol triphosphate in [32P]orthophosphate-labeled platelets . *Anal Biochem* . 1986 ; 154 : 414 - 9
- 52 . Barker CJ , Berggren PO . The role of inositol and the principles of labelling, extraction, and analysis of inositides in mammalian cells . *Methods Mol Biol* . 2010 ; 645 : 1 - 19
- 53 . Sauer K , Huang YH , Lin H , Sandberg M , Mayr GW . Phosphoinositide and inositol phosphate analysis in lymphocyte activation . *Curr Protoc Immunol* . 2009 ; Chapter 11 : (Unit11 ) 1 -
- 54 . Eglén RM . Functional G protein-coupled receptor assays for primary and secondary screening . *Comb Chem High Throughput Screen* . 2005 ; 8 : 311 - 8

- 55 . Trinquet E , Fink M , Bazin H , Grillet F , Maurin F , Bourrier E . D-myo-inositol 1-phosphate as a surrogate of D-myo-inositol 1,4,5-tris phosphate to monitor G protein-coupled receptor activation . *Anal Biochem* . 2006 ; 358 : 126 - 35
- 56 . Paredes RM , Etzler JC , Watts LT , Zheng W , Lechleiter JD . Chemical calcium indicators . *Methods* . 2008 ; 46 : 143 - 51
- 57 . Shimomura O , Johnson FH , Saiga Y . Extraction, purification and properties of aequorin, a bioluminescent protein from the luminous hydromedusan, *Aequorea* . *J Cell Comp Physiol* . 1962 ; 59 : 223 - 39
- 58 . Pinton P , Rimessi A , Romagnoli A , Prandini A , Rizzuto R . Biosensors for the detection of calcium and pH . *Methods Cell Biol* . 2007 ; 80 : 297 - 325
- 59 . Miyawaki A , Llopis J , Heim R , McCaffery JM , Adams JA , Ikura M . Fluorescent indicators for Ca<sup>2+</sup> based on green fluorescent proteins and calmodulin . *Nature* . 1997 ; 388 : 882 - 7
- 60 . Demaurex N . Calcium measurements in organelles with Ca<sup>2+</sup>-sensitive fluorescent proteins . *Cell Calcium* . 2005 ; 38 : 213 - 22
- 61 . Palmer AE , Tsien RY . Measuring calcium signaling using genetically targetable fluorescent indicators . *Nat Protoc* . 2006 ; 1 : 1057 - 65
- 62 . Riobo NA , Manning DR . Receptors coupled to heterotrimeric G proteins of the G12 family . *Trends Pharmacol Sci* . 2005 ; 26 : 146 - 54
- 63 . Worzfeld T , Wettschreck N , Offermanns S . G(12)/G(13)-mediated signalling in mammalian physiology and disease . *Trends Pharmacol Sci* . 2008 ; 29 : 582 - 9
- 64 . Regard JB , Kataoka H , Cano DA , Camerer E , Yin L , Zheng YW . Probing cell type-specific functions of Gi in vivo identifies GPCR regulators of insulin secretion . *J Clin Invest* . 2007 ; 117 : 4034 - 43
- 65 . Higashijima T , Uzu S , Nakajima T , Ross EM . Mastoparan, a peptide toxin from wasp venom, mimics receptors by activating GTP-binding regulatory proteins (G proteins) . *J Biol Chem* . 1988 ; 263 : 6491 - 4
- 66 . Sukumar M , Ross EM , Higashijima T . A Gs-selective analog of the receptor-mimetic peptide mastoparan binds to Gs alpha in a kinked helical conformation . *Biochemistry* . 1997 ; 36 : 3632 - 9
- 67 . Van Dop C , Tsubokawa M , Bourne HR , Ramachandran J . Amino acid sequence of retinal transducin at the site ADP-ribosylated by cholera toxin . *J Biol Chem* . 1984 ; 259 : 696 - 8
- 68 . Northup JK , Sternweis PC , Smigel MD , Schleifer LS , Ross EM , Gilman AG . Purification of the regulatory component of adenylate cyclase . *Proc Natl Acad Sci U S A* . 1980 ; 77 : 6516 - 20
- 69 . Freissmuth M , Boehm S , Beindl W , Nickel P , Ijzerman AP , Hohenegger M . Suramin analogues as subtype-selective G protein inhibitors . *Mol Pharmacol* . 1996 ; 49 : 602 - 11
- 70 . Hohenegger M , Waldhoer M , Beindl W , Boing B , Kreimeyer A , Nickel P . Galpha-selective G protein antagonists . *Proc Natl Acad Sci U S A* . 1998 ; 95 : 346 - 51
- 71 . Wilson BA , Zhu X , Ho M , Lu L . Pasteurella multocida toxin activates the inositol triphosphate signaling pathway in *Xenopus* oocytes via G(q)alpha-coupled phospholipase C-beta1 . *J Biol Chem* . 1997 ; 272 : 1268 - 75
- 72 . Zywiets A , Gohla A , Schmelz M , Schultz G , Offermanns S . Pleiotropic effects of Pasteurella multocida toxin are mediated by Gq-dependent and -independent mechanisms. involvement of Gq but not G11 . *J Biol Chem* . 2001 ; 276 : 3840 - 5
- 73 . Wilson BA , Ho M . Pasteurella multocida toxin as a tool for studying Gq signal transduction . *Rev Physiol Biochem Pharmacol* . 2004 ; 152 : 93 - 109
- 74 . Kawasaki T , Taniguchi M , Moritani Y , Hayashi K , Saito T , Takasaki J . Antithrombotic and thrombolytic efficacy of YM-254890, a G q/11 inhibitor, in a rat model of arterial thrombosis . *Thromb Haemost* . 2003 ; 90 : 406 - 13
- 75 . Nishimura A , Kitano K , Takasaki J , Taniguchi M , Mizuno N , Tago K . Structural basis for the specific inhibition of heterotrimeric Gq protein by a small molecule . *Proc Natl Acad Sci U S A* . 2010 ; 107 : 13666 - 71
- 76 . Ayoub MA , Damian M , Gspach C , Ferrandis E , Lavergne O , De Wever O . Inhibition of heterotrimeric G protein signaling by a small molecule acting on Galpha subunit . *J Biol Chem* . 2009 ; 284 : 29136 - 45
- 77 . Rasenick MM , Watanabe M , Lazarevic MB , Hatta S , Hamm HE . Synthetic peptides as probes for G protein function. Carboxyl-terminal G alpha s peptides mimic Gs and evoke high affinity agonist binding to beta-adrenergic receptors . *J Biol Chem* . 1994 ; 269 : 21519 - 25
- 78 . Gilchrist A , Vanhauwe JF , Li A , Thomas TO , Voyno-Yasenetskaya T , Hamm HE . G alpha minigenes expressing C-terminal peptides serve as specific inhibitors of thrombin-mediated endothelial activation . *J Biol Chem* . 2001 ; 276 : 25672 - 9
- 79 . Gilchrist A , Li A , Hamm HE . G alpha COOH-terminal minigene vectors dissect heterotrimeric G protein signaling . *Sci STKE* . 2002 ; 2002 : p11 -
- 80 . Atwood BK , Lopez J , Wager-Miller J , Mackie K , Straiker A . Expression of G protein-coupled receptors and related proteins in HEK293, AtT20, BV2, and N18 cell lines as revealed by microarray analysis . *BMC Genomics* . 2011 ; 12 : 14 -
- 81 . Wettschreck N , Moers A , Offermanns S . Mouse models to study G-protein-mediated signaling . *Pharmacol Ther* . 2004 ; 101 : 75 - 89
- 82 . Krumins AM , Gilman AG . Targeted knockdown of G protein subunits selectively prevents receptor-mediated modulation of effectors and reveals complex changes in non-targeted signaling proteins . *J Biol Chem* . 2006 ; 281 : 10250 - 62
- 83 . Hilf G , Gierschik P , Jakobs KH . Muscarinic acetylcholine receptor-stimulated binding of guanosine 5'-O-(3-thiotriphosphate) to guanine-nucleotide-binding proteins in cardiac membranes . *Eur J Biochem* . 1989 ; 186 : 725 - 31
- 84 . Wieland T , Liedel K , Kaldenberg-Stasch S , Meyer zu Heringdorf D , Schmiel M , Jakobs KH . Analysis of receptor-G protein interactions in permeabilized cells . *Naunyn Schmiedebergs Arch Pharmacol* . 1995 ; 351 : 329 - 36
- 85 . Sim LJ , Selley DE , Childers SR . In vitro autoradiography of receptor-activated G proteins in rat brain by agonist-stimulated guanylyl 5'-[gamma-[35S]thio]-triphosphate binding . *Proc Natl Acad Sci U S A* . 1995 ; 92 : 7242 - 6
- 86 . Harrison C , Traynor JR . The [35S]GTPgammaS binding assay: approaches and applications in pharmacology . *Life Sci* . 2003 ; 74 : 489 - 508
- 87 . Newman-Tancredi A , Conte C , Chaput C , Verrielle L , Millan MJ . Agonist and inverse agonist efficacy at human recombinant serotonin 5-HT1A receptors as a function of receptor:G-protein stoichiometry . *Neuropharmacology* . 1997 ; 36 : 451 - 9
- 88 . Barr AJ , Brass LF , Manning DR . Reconstitution of receptors and GTP-binding regulatory proteins (G proteins) in Sf9 cells. A direct evaluation of selectivity in receptor. G protein coupling . *J Biol Chem* . 1997 ; 272 : 2223 - 9
- 89 . Seifert R , Lee TW , Lam VT , Kobilka BK . Reconstitution of beta2-adrenoceptor-GTP-binding-protein interaction in Sf9 cells--high coupling efficiency in a beta2-adrenoceptor-G(s alpha) fusion protein . *Eur J Biochem* . 1998 ; 255 : 369 - 82
- 90 . Kenakin T . Ligand-selective receptor conformations revisited: the promise and the problem . *Trends Pharmacol Sci* . 2003 ; 24 : 346 - 54
- 91 . Pauwels PJ , Rauli I , Wurch T , Colpaert FC . Evidence for protean agonism of RX 831003 at alpha 2A-adrenoceptors by co-expression with different G alpha protein subunits . *Neuropharmacology* . 2002 ; 42 : 855 - 63
- 92 . Windh RT , Lee MJ , Hla T , An S , Barr AJ , Manning DR . Differential coupling of the sphingosine 1-phosphate receptors Edg-1, Edg-3, and H218/Edg-5 to the G(i), G(q), and G(12) families of heterotrimeric G proteins . *J Biol Chem* . 1999 ; 274 : 27351 - 8
- 93 . McLean AJ , Zeng FY , Behan D , Chalmers D , Milligan G . Generation and analysis of constitutively active and physically destabilized mutants of the human beta(1)-adrenoceptor . *Mol Pharmacol* . 2002 ; 62 : 747 - 55
- 94 . DeLapp NW . The antibody-capture [(35)S]GTPgammaS scintillation proximity assay: a powerful emerging technique for analysis of GPCR pharmacology . *Trends Pharmacol Sci* . 2004 ; 25 : 400 - 1
- 95 . Johnson EN , Shi X , Cassaday J , Ferrer M , Strulovici B , Kunapuli P . A 1,536-well [(35)S]GTPgammaS scintillation proximity binding assay for ultra-high-throughput screening of an orphan galphai-coupled GPCR . *Assay Drug Dev Technol* . 2008 ; 6 : 327 - 37
- 96 . Frang H , Mukkala VM , Syysto R , Ollikka P , Hurskainen P , Scheinin M . Nonradioactive GTP binding assay to monitor activation of g protein-coupled receptors . *Assay Drug Dev Technol* . 2003 ; 1 : 275 - 80
- 97 . Koval A , Kopein D , Purvanov V , Katanaev VL . Europium-labeled GTP as a general nonradioactive substitute for [(35)S]GTPgammaS in high-throughput G protein studies . *Anal Biochem* . 2010 ; 397 : 202 - 7
- 98 . McEwen DP , Gee KR , Kang HC , Neubig RR . Fluorescent BODIPY-GTP analogs: real-time measurement of nucleotide binding to G proteins . *Anal Biochem* . 2001 ; 291 : 109 - 17


- 99 . Jameson EE , Roof RA , Whorton MR , Mosberg HI , Sunahara RK , Neubig RR . Real-time detection of basal and stimulated G protein GTPase activity using fluorescent GTP analogues . *J Biol Chem* . 2005 ; 280 : 7712 - 9
- 100 . Bertin B , Freissmuth M , Jockers R , Strosberg AD , Marullo S . Cellular signaling by an agonist-activated receptor/Gs alpha fusion protein . *Proc Natl Acad Sci U S A* . 1994 ; 91 : 8827 - 31
- 101 . Wise A , Carr IC , Milligan G . Measurement of agonist-induced guanine nucleotide turnover by the G-protein Gi1alpha when constrained within an alpha2A-adrenoceptor-Gi1alpha fusion protein . *Biochem J* . 1997 ; 325 : ( Pt 1 ) 17 - 21
- 102 . Massotte D , Brillet K , Kieffer B , Milligan G . Agonists activate Gi1 alpha or Gi2 alpha fused to the human mu opioid receptor differently . *J Neurochem* . 2002 ; 81 : 1372 - 82
- 103 . Lane JR , Powney B , Wise A , Rees S , Milligan G . Protean agonism at the dopamine D2 receptor: (S)-3-(3-hydroxyphenyl)-N-propylpiperidine is an agonist for activation of Go1 but an antagonist/inverse agonist for Gi1,Gi2, and Gi3 . *Mol Pharmacol* . 2007 ; 71 : 1349 - 59
- 104 . Wenzel-Seifert K , Seifert R . Molecular analysis of beta(2)-adrenoceptor coupling to G(s)-, G(i)-, and G(q)-proteins . *Mol Pharmacol* . 2000 ; 58 : 954 - 66
- 105 . Milligan G , Parenty G , Stoddart LA , Lane JR . Novel pharmacological applications of G-protein-coupled receptor-G protein fusions . *Curr Opin Pharmacol* . 2007 ; 7 : 521 - 6
- 106 . Pascal G , Milligan G . Functional complementation and the analysis of opioid receptor homodimerization . *Mol Pharmacol* . 2005 ; 68 : 905 - 15
- 107 . Han Y , Moreira IS , Urizar E , Weinstein H , Javitch JA . Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation . *Nat Chem Biol* . 2009 ; 5 : 688 - 95
- 108 . Salamon Z , Macleod HA , Tollin G . Coupled plasmon-waveguide resonators: a new spectroscopic tool for probing proteolipid film structure and properties . *Biophys J* . 1997 ; 73 : 2791 - 7
- 109 . Tollin G , Salamon Z , Hruby VJ . Techniques: plasmon-waveguide resonance (PWR) spectroscopy as a tool to study ligand-GPCR interactions . *Trends Pharmacol Sci* . 2003 ; 24 : 655 - 9
- 110 . Alves ID , Salamon Z , Varga E , Yamamura HI , Tollin G , Hruby VJ . Direct observation of G-protein binding to the human delta-opioid receptor using plasmon-waveguide resonance spectroscopy . *J Biol Chem* . 2003 ; 278 : 48890 - 7
- 111 . Salamon Z , Tollin G , Alves I , Hruby V . Chapter 6. Plasmon resonance methods in membrane protein biology applications to GPCR signaling . *Methods Enzymol* . 2009 ; 461 : 123 - 46
- 112 . Devanathan S , Yao Z , Salamon Z , Kobilka B , Tollin G . Plasmon-waveguide resonance studies of ligand binding to the human beta 2-adrenergic receptor . *Biochemistry* . 2004 ; 43 : 3280 - 8
- 113 . Alves ID , Delaroche D , Mouillac B , Salamon Z , Tollin G , Hruby VJ . The two NK-1 binding sites correspond to distinct, independent, and non-interconvertible receptor conformational states as confirmed by plasmon-waveguide resonance spectroscopy . *Biochemistry* . 2006 ; 45 : 5309 - 18
- 114 . Georgieva T , Devanathan S , Stropova D , Park CK , Salamon Z , Tollin G . Unique agonist-bound cannabinoid CB1 receptor conformations indicate agonist specificity in signaling . *Eur J Pharmacol* . 2008 ; 581 : 19 - 29
- 115 . Förster T . *Naturwissenschaften* . 1946 ; 6 : 166 - 75
- 116 . Boute N , Jockers R , Issad T . The use of resonance energy transfer in high-throughput screening: BRET versus FRET . *Trends Pharmacol Sci* . 2002 ; 23 : 351 - 4
- 117 . Pflieger KD , Eidne KA . Monitoring the formation of dynamic G-protein-coupled receptor-protein complexes in living cells . *Biochem J* . 2005 ; 385 : 625 - 37
- 118 . Dacres H , Dumancic MM , Horne I , Trowell SC . Direct comparison of bioluminescence-based resonance energy transfer methods for monitoring of proteolytic cleavage . *Anal Biochem* . 2009 ; 385 : 194 - 202
- 119 . Loening AM , Wu AM , Gambhir SS . Red-shifted Renilla reniformis luciferase variants for imaging in living subjects . *Nat Methods* . 2007 ; 4 : 641 - 3
- 120 . De A , Loening AM , Gambhir SS . An improved bioluminescence resonance energy transfer strategy for imaging intracellular events in single cells and living subjects . *Cancer Res* . 2007 ; 67 : 7175 - 83
- 121 . Gales C , Rebois RV , Hogue M , Trieu P , Breit A , Hebert TE . Real-time monitoring of receptor and G-protein interactions in living cells . *Nat Methods* . 2005 ; 2 : 177 - 84
- 122 . Hein P , Frank M , Hoffmann C , Lohse MJ , Bunemann M . Dynamics of receptor/G protein coupling in living cells . *Embo J* . 2005 ; 24 : 4106 - 14
- 123 . Audet N , Gales C , Archer-Lahlou E , Vallieres M , Schiller PW , Bouvier M . Bioluminescence resonance energy transfer assays reveal ligand-specific conformational changes within preformed signaling complexes containing delta-opioid receptors and heterotrimeric G proteins . *J Biol Chem* . 2008 ; 283 : 15078 - 88
- 124 . Galandrin S , Oligny-Longpre G , Bonin H , Ogawa K , Gales C , Bouvier M . Conformational rearrangements and signaling cascades involved in ligand-biased mitogen-activated protein kinase signaling through the beta1-adrenergic receptor . *Mol Pharmacol* . 2008 ; 74 : 162 - 72
- 125 . Ayoub MA , Maurel D , Binet V , Fink M , Prezeau L , Ansanay H . Real-time analysis of agonist-induced activation of protease-activated receptor 1/Galphi1 protein complex measured by bioluminescence resonance energy transfer in living cells . *Mol Pharmacol* . 2007 ; 71 : 1329 - 40
- 126 . Ayoub MA , Trinquet E , Pflieger KD , Pin JP . Differential association modes of the thrombin receptor PAR1 with Galphi1, Galphi2, and beta-arrestin 1 . *Faseb J* . 2010 ; 24 : 3522 - 35
- 127 . Janetopoulos C , Jin T , Devreotes P . Receptor-mediated activation of heterotrimeric G-proteins in living cells . *Science* . 2001 ; 291 : 2408 - 11
- 128 . Azpiazu I , Gautam N . A fluorescence resonance energy transfer-based sensor indicates that receptor access to a G protein is unrestricted in a living mammalian cell . *J Biol Chem* . 2004 ; 279 : 27709 - 18
- 129 . Frank M , Thumer L , Lohse MJ , Bunemann M . G Protein activation without subunit dissociation depends on a G{alpha}(i)-specific region . *J Biol Chem* . 2005 ; 280 : 24584 - 90
- 130 . Gibson SK , Gilman AG . Galpha and Gbeta subunits both define selectivity of G protein activation by alpha2-adrenergic receptors . *Proc Natl Acad Sci U S A* . 2006 ; 103 : 212 - 7
- 131 . Nobles M , Benians A , Tinker A . Heterotrimeric G proteins precouple with G protein-coupled receptors in living cells . *Proc Natl Acad Sci U S A* . 2005 ; 102 : 18706 - 11
- 132 . Chisari M , Saini DK , Cho JH , Kalyanaraman V , Gautam N . G protein subunit dissociation and translocation regulate cellular response to receptor stimulation . *PLoS One* . 2009 ; 4 : e7797 -
- 133 . Lohse MJ , Vilaradaga JP , Bunemann M . Direct optical recording of intrinsic efficacy at a G protein-coupled receptor . *Life Sci* . 2003 ; 74 : 397 - 404
- 134 . Gao ZG , Jacobson KA . Translocation of arrestin induced by human A(3) adenosine receptor ligands in an engineered cell line: comparison with G protein-dependent pathways . *Pharmacol Res* . 2008 ; 57 : 303 - 11
- 135 . Whalen EJ , Rajagopal S , Lefkowitz RJ . Therapeutic potential of beta-arrestin- and G protein-biased agonists . *Trends Mol Med* . 2011 ; 17 : 126 - 39
- 136 . Bisello A , Chorev M , Rosenblatt M , Monticelli L , Mierke DF , Ferrari SL . Selective ligand-induced stabilization of active and desensitized parathyroid hormone type 1 receptor conformations . *J Biol Chem* . 2002 ; 277 : 38524 - 30
- 137 . Wehbi V , Decourtye J , Piketty V , Durand G , Reiter E , Maurel MC . Selective modulation of follicle-stimulating hormone signaling pathways with enhancing equine chorionic gonadotropin/antibody immune complexes . *Endocrinology* . 2010 ; 151 : 2788 - 99
- 138 . Rafei M , Berchiche YA , Birman E , Boivin MN , Young YK , Wu JH . An engineered GM-CSF-CCL2 fusokine is a potent inhibitor of CCR2-driven inflammation as demonstrated in a murine model of inflammatory arthritis . *J Immunol* . 2009 ; 183 : 1759 - 66
- 139 . Jorgensen R , Kubale V , Vrecl M , Schwartz TW , Elling CE . Oxyntomodulin differentially affects glucagon-like peptide-1 receptor beta-arrestin recruitment and signaling through Galpha(s) . *J Pharmacol Exp Ther* . 2007 ; 322 : 148 - 54
- 140 . Reversi A , Rimoldi V , Marrocco T , Cassoni P , Bussolati G , Parenti M . The oxytocin receptor antagonist atosiban inhibits cell growth via a "biased agonist" mechanism . *J Biol Chem* . 2005 ; 280 : 16311 - 8
- 141 . Sensken SC , Staubert C , Keul P , Levkau B , Schoneberg T , Graler MH . Selective activation of G alpha i mediated signalling of S1P3 by FTY720-phosphate . *Cell Signal* . 2008 ; 20 : 1125 - 33

- 142 . Rajagopal S , Rajagopal K , Lefkowitz RJ . Teaching old receptors new tricks: biasing seven-transmembrane receptors . *Nat Rev Drug Discov* . 2010 ; 9 : 373 - 86
- 143 . Wei H , Ahn S , Shenoy SK , Karnik SS , Hunyady L , Luttrell LM . Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2 . *Proc Natl Acad Sci U S A* . 2003 ; 100 : 10782 - 7
- 144 . Kim IM , Tilley DG , Chen J , Salazar NC , Whalen EJ , Violin JD . Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation . *Proc Natl Acad Sci U S A* . 2008 ; 105 : 14555 - 60
- 145 . Wisler JW , DeWire SM , Whalen EJ , Violin JD , Drake MT , Ahn S . A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling . *Proc Natl Acad Sci U S A* . 2007 ; 104 : 16657 - 62
- 146 . Rajagopal S , Kim J , Ahn S , Craig S , Lam CM , Gerard NP . Beta-arrestin- but not G protein-mediated signaling by the "decoy" receptor CXCR7 . *Proc Natl Acad Sci U S A* . 2010 ; 107 : 628 - 32
- 147 . Verkaar F , van Rosmalen JW , Blomenrohr M , van Koppen CJ , Blankesteyn WM , Smits JF . G protein-independent cell-based assays for drug discovery on seven-transmembrane receptors . *Biotechnol Annu Rev* . 2008 ; 14 : 253 - 74
- 148 . Drake MT , Violin JD , Whalen EJ , Wisler JW , Shenoy SK , Lefkowitz RJ . beta-arrestin-biased agonism at the beta2-adrenergic receptor . *J Biol Chem* . 2008 ; 283 : 5669 - 76
- 149 . Hansen JL , Aplin M , Hansen JT , Christensen GL , Bonde MM , Schneider M . The human angiotensin AT(1) receptor supports G protein-independent extracellular signal-regulated kinase 1/2 activation and cellular proliferation . *Eur J Pharmacol* . 2008 ; 590 : 255 - 63
- 150 . Luker KE , Gupta M , Luker GD . Imaging CXCR4 signaling with firefly luciferase complementation . *Anal Chem* . 2008 ; 80 : 5565 - 73
- 151 . van Der Lee MM , Bras M , van Koppen CJ , Zaman GJ . beta-Arrestin recruitment assay for the identification of agonists of the sphingosine 1-phosphate receptor EDG1 . *J Biomol Screen* . 2008 ; 13 : 986 - 98
- 152 . Charest PG , Terrillon S , Bouvier M . Monitoring agonist-promoted conformational changes of beta-arrestin in living cells by intramolecular BRET . *EMBO Rep* . 2005 ; 6 : 334 - 40
- 153 . Shukla AK , Violin JD , Whalen EJ , Gesty-Palmer D , Shenoy SK , Lefkowitz RJ . Distinct conformational changes in beta-arrestin report biased agonism at seven-transmembrane receptors . *Proc Natl Acad Sci U S A* . 2008 ; 105 : 9988 - 93
- 154 . Luttrell LM , Ferguson SS , Daaka Y , Miller WE , Maudsley S , Della Rocca GJ . Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes . *Science* . 1999 ; 283 : 655 - 61
- 155 . Ahn S , Shenoy SK , Wei H , Lefkowitz RJ . Differential kinetic and spatial patterns of beta-arrestin and G protein-mediated ERK activation by the angiotensin II receptor . *J Biol Chem* . 2004 ; 279 : 35518 - 25
- 156 . Callander GE , Thomas WG , Bathgate RA . Prolonged RXFP1 and RXFP2 signaling can be explained by poor internalization and a lack of beta-arrestin recruitment . *Am J Physiol Cell Physiol* . 2009 ; 296 : C1058 - 66
- 157 . Milligan G . Principles: extending the utility of [35S]GTP gamma S binding assays . *Trends Pharmacol Sci* . 2003 ; 24 : 87 - 90
- 158 . Leduc M , Breton B , Gales C , Le Gouill C , Bouvier M , Chemtob S . Functional selectivity of natural and synthetic prostaglandin EP4 receptor ligands . *J Pharmacol Exp Ther* . 2009 ; 331 : 297 - 307
- 159 . Galandrin S , Bouvier M . Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy . *Mol Pharmacol* . 2006 ; 70 : 1575 - 84
- 160 . Luttrell LM , Lefkowitz RJ . The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals . *J Cell Sci* . 2002 ; 115 : 455 - 65




**Fig. 1**

Schematic complex in the plasma membrane between rhodopsin (gray; PDB code 1GZM) and the inactive heterotrimeric G protein composed of  $\alpha_{11}$ ,  $\beta_1$ , and  $\gamma_2$  subunits (light blue/violet, red and yellow respectively; PDB code 1GG2).  $G\alpha_{11}$  N-terminal helix ( $\alpha_N$ ) is shown in brown, while  $G\alpha_{11}$ -GTPase and  $G\alpha_{11}$ -helical domains ( $\alpha_{11}H$ ) are in light blue and violet respectively. Linker 1 connecting  $G\alpha_{11}$ -GTPase to the  $G\alpha_{11}H$  is represented in green. Both  $G\alpha_{11}N$  and  $G\gamma_2C$ -terminal helix ( $\gamma_2C$ ) are anchored to the membrane through lipid modification.




**Fig. 2**

Heterotrimeric G protein activation cycle. In the absence of agonist (**1**, basal state),  $G\alpha GDP-\beta\gamma$  heterotrimeric G protein forms a tight inactive complex dissociated from the receptor. The activation of the receptor by the agonist promotes recruitment of  $G\alpha\beta\gamma$  to the receptor and the subsequent GDP/GTP exchange at the level of the  $G\alpha$  subunit (**2**, association). This nucleotide exchange then leads to the dissociation of the receptor and also of the  $G\alpha$ -GTP and  $G\beta\gamma$  subunits, which are now able to activate their effectors (**3**, dissociation). The activation cycle is terminated by the  $G\alpha$  intrinsic GTPase activity which allows GTP hydrolysis and the reassociation of  $G\alpha$ -GDP with  $G\beta\gamma$  subunits so to restore the inactive basal state (1).



**Fig. 3**

Schematic representation of heterotrimeric G protein canonical pathways.  $G\alpha_s$ -coupled receptors usually promote direct activation of adenylyl cyclase (AC) leading to intracellular cAMP production which can directly bind and activate Protein Kinase A (PKA) or Exchange Protein directly Activated by cAMP (Epac) effectors. On the contrary,  $G\alpha_{i/o}$ -coupled receptors counteract the actions of  $G_s$ -GPCRs and inhibit AC activity even if they can also activate it through  $G\beta\gamma$  subunits. The main effector of  $G\alpha_{q/11}$ -coupled receptors is phospholipase C which catalyzes the cleavage of membrane-bound phosphatidylinositol 4,5-bisphosphate ( $PIP_2$ ) into the second messengers inositol (1,4,5) triphosphate ( $IP_3$ ) and diacylglycerol (DAG).  $IP_3$  acts on  $IP_3$  receptors found in the membrane of the endoplasmic reticulum (ER) to elicit  $Ca^{2+}$  release from the ER, while DAG diffuses along the plasma membrane where it may activate membrane localized forms of Protein Kinase C (PKC). The effectors of the  $G\alpha_{12/13}$  pathway are RhoGEFs which, when bound to  $G\alpha_{12/13}$  allosterically, activate the cytosolic small GTPase, Rho. Then, active Rho-GTP can activate various proteins responsible for cytoskeleton regulation.




**Fig. 4**

Resonance Energy transfer (RET). (A) RET is a non radiative energy transfer which occurs between an energy donor and an energy acceptor over a restricted distance. When the energy donor is excited and is in close proximity ( $< 100 \text{ \AA}$ ) to the donor, the energy released is then transferred by resonance ( $R$ ) to the energy acceptor, which in turns becomes excited and emits at a different wavelength to that of the donor. (B) Depending on the nature of the energy donor we distinguish two RET: i/FRET (Fluorescence Resonance Energy Transfer) with a fluorescent energy donor excited by external light and ii/BRET (Bioluminescence Resonance Energy Transfer) using an enzymatic energy donor (*Renilla* Luciferase) excited by degradation of its substrate (coelenterazine).

**A****B****Fig. 5**

The basics of BRET<sup>1</sup> and BRET<sup>2</sup>. BRET<sup>1</sup> and BRET<sup>2</sup> are based on the use of different coelenterazine substrates (Coelenterazine *h* for BRET<sup>1</sup> and DeepBlueC in BRET<sup>2</sup>) which confer specific spectral properties to *Renilla* luciferase. The energy acceptor is then adapted to the emission wavelength of *Renilla* luciferase in each cases (eYFP in BRET<sup>1</sup> and GFP10 in BRET<sup>2</sup>).





**Fig. 6**

Configurations of the different BRET assays used to probe receptor-mediated G protein activation. Schematic representation of a GPCR (purple, Rhodopsin PDB code 1L9H) and a heterotrimeric G protein composed of  $\alpha_{i1}$ ,  $\beta_1$ , and  $\gamma_2$  subunits (light blue, red and yellow respectively; PDB code 1GG2) interacting at the plasma membrane, fused to luciferase (blue; PDB code 1LC1) or to GFP (green; PDB code 1GFL) as indicated. **(A)** BRET monitoring receptor- $G\alpha$  interaction. **(B)** BRET monitoring  $G\alpha/G\gamma$  interaction.



**A**

**Receptor- $G\alpha$  interaction**



**B**


**$G\alpha$ - $G\gamma$  interaction**



**Fig. 7**

G $\alpha$ -91R luc/GFP10-G $\gamma$  BRET probe is a direct sensor of G protein activation. (**A**) Localization of the BRET probes (Rluc and GFP10) within G $\alpha_{i1}$   $\beta_1$   $\gamma_2$  G protein. (**B**) Schematic representation of structural rearrangement within G $\alpha_{i1}$   $\beta_1$   $\gamma_2$  depicted by BRET following receptor activation. R luc probes within G $\alpha_{i1}$  are shown in blue while GFP probe at the C-terminal of G $\gamma_2$  is shown in green. The scheme represents an opening of G $\alpha_{i1}$ -GTPase and G $\alpha_{i1}$  H through linker 1 (like a clamp), thus increasing R Luc91-G $\gamma_2$  N and R Luc122-G $\gamma_2$  N distance. These rearrangements would thus create an exit route for the guanine nucleotide and thus measure directly the activation state of the G protein.

**A**



**B**

